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ABSTRACT

While the latent genome of most Herpesviruses persists as a nuclear circular
episome, previous research has suggested that Human Herpesvirus 6 (HHV-6) may
integrate into host cell chromosomes, and be vertically transmitted in the germ-line.
Because the HHV-6 genome encodes a perfect TTAGGG telomere repeat array at the
right end direct repeat (DRR) and an imperfect TTAGGG repeat at the end of the left end
direct repeat (DRL), we established a hypothesis that during latency, the HHV-6A and
HHV-6B genome integrates into the telomeres of human chromosomes through
homologous recombination with the n(TTAGGG) viral repeats, and the integrated virus
can be induced to lytic replication.
We sought, first, to definitively illustrate the in vitro and in vivo integration of
HHV-6A and HHV-6B. Following infection of naïve Jjhan and HEK-293 cell lines by
HHV-6A and Molt3 cell line by HHV-6B, the virus integrated into telomere of
chromosomes. Next, peripheral blood mononuclear cells (PBMCs) were isolated from
families in which several members, including at least one parent and child, had
unusually high copy numbers of HHV-6 DNA per ml of blood. FISH confirmed that HHV6 DNA co-localized with telomeric regions of one allele on chromosomes 17p13.3,
18q23, and 22q13.3, while the integration site was identical among members of the
same family. Partial sequencing of the viral genome identified the same integrated
HHV-6A strain within members of families, confirming vertical transmission of the viral
genome through the germ-line [inherited HHV-6 (iHHV-6)].
xi

Amplification and sequencing of the HHV-6A and more recently HHV-6B viralchromosome junction identified DRR integrated into the telomere directly adjacent to the
subtelomere of the chromosome. After mapping the DRR of iHHV-6, we subsequently
focused on determining if the DRL was present in the integrated genome and whether
the remaining telomere sequence of the chromosome was extended beyond the DRL.
Southern hybridization of PCR amplified HHV-6 integrated cell lines and iHHV-6 patients
PBMCs indicate the presence of DRL within the integrated viral genome. Moreover, the
tandem array of telomere repeats [(TTAGGG)n] at the end of chromosome was shown to
extend beyond the DRL of iHHV-6. Therefore, the genomic structure of the iHHV-6 is as
follows: chromosome-subtelomere-(TTAGGG)5-41-DRR-U-DRL-(TTAGGG)n.
During latent integration, no circular episomes were detected even by PCR.
However, trichostatin-A treatment of PBMCs and in vitro integrated HEK-293 cells
induced the reactivation of iHHV-6 from its latent integrated state. We demonstrated the
induction of integrated iHHV-6 with trichostatin-A lead to the excision of the integrated
genome and generation of the U-DR-U junction which signifies circularization and/or
concatemer formation of the viral genome through rolling-circle replication. Taken
together, the data suggests that HHV-6A and HHV-6B are unique among human
herpesviruses: they specifically and efficiently integrate into telomeres of chromosomes
during latency rather than forming episomes, and the integrated viral genome is capable
of producing virions.

xii

INTRODUCTION

Classification of Human Herpesviruses
Human Herpesviruses are ubiquitous and belong to the family of Herpesviridae
which features large enveloped virions. The Herpesvirus virion contains a single double
stranded DNA (dsDNA) genome ranging from 150 to 230 kbp that is packaged in an
icosahedral capsid (1). The viral nucleocapsid is surrounded by a proteinaceous
tegument often consisting of proteins necessary for initiation of viral genome replication
and degradation of cellular mRNAs. Following the capsid and tegument layers, the
virion is encased by an envelope that is obtained from the host cell’s plasma membrane
or cellular organelles during the process of budding.
Human Herpesviruses can be subdivided into three major subfamilies
characterized by their genome sequence and structure, as well as host cell range during
lytic and latent infection (Table 1) (1). The Alphaherpesviruses: Herpes Simplex virus
type 1 (HSV-1), HSV-2, and Varicella Zoster virus (VZV) infect and establish latency
within neurons. The Gamaherpesviruses: Epstein-Barr virus (EBV) and the Kaposi’s
Sarcoma-associated Herpesvirus (KSHV) infect B-lymphocytes, while various malignant
diseases can occur during latent infection. Betaherpesviruses: Human Herpesvirus 6A
(HHV-6A), HHV-6B, HHV-7, and Cytomegalovirus (CMV) are characterized upon their
ability to establish latent infection in monocytes and retain similarities in their genes and
genomic structure amongst these viruses.

1

Table 1. Classification of Human Herpesviruses (1).
Common Name

Abbreviation

Subfamily

Genome
Size (kbp)

HHV-1

Herpes Simplex virus 1

HSV-1

Alpha

152

HHV-2

Herpes Simplex virus 2

HSV-2

Alpha

155

HHV-3

Varicella-Zoster virus

VZV

Alpha

125

HHV-4

Epstein-Barr virus

EBV

Gamma

172

HHV-5

Cytomegalovirus

CMV

Beta

230

HHV-6A

Human Herpesvirus 6A

HHV-6A

Beta

159

HHV-6B

Human Herpesvirus 6B

HHV-6B

Beta

162

HHV-7

Human Herpesvirus 7

HHV-7

Beta

145

HHV-8

Kaposi’s Sarcomaassociated Herpesvirus

KSHV

Gamma

170

Designation

Human Herpesvirus 6 (HHV-6) was initially recognized as Human BLymphotropic virus (HBLV) by Salahuddin et al. in 1986, given that the virus was
isolated from B-lymphocytes of patients infected with HIV, HTLV, and lymphoproliferative
disorders (2). However, through further molecular and clinical studies, as well as
sequencing of the viral genome, the virus was found to include two different species;
HHV-6A and HHV-6B (3-6). HHV-6A and HHV-6B have been shown to productively
infect T-lymphocytes, monocytes/macrophages, human umbilical cord blood, and
various cell lines (7-11).
Furthermore, in 1988 Yamanishi et al. established that HHV-6B primary infection
in young children is the etiological agent of exanthema subitum (roseola infantum),
which is characterized by high fever, diarrhea, and a mild skin rash along the trunk,
neck, and face (5, 12). Serologic studies have found that by the age of two, 90% of
children have acquired a primary HHV-6 infection (13, 14). As for HHV-6A, the virus has
been associated with several adult diseases; including cofactor in AIDS progression, and
2

various neurological disorders including encephalitis, ataxia, seizures, and chronic
fatigue syndrome, however the causal link between human disease and virus infection
remains to be fully elucidated (6, 15-23).

Genome Organization of Human Herpesviruses
The genome of Human Herpesviruses are linear double-stranded DNA ranging in
sizes from 150 to 230 kbp (1). Human Herpesviruses also contain repetitive sequences
longer than 100bp that vary among sequence, location, and complexity among the
different species (Fig. 1). Terminal repeats (TR) and direct repeats (DR) located at the
termini of herpesvirus genomes permit circularization. Several Human Herpesviruses
also encode inverted repeats (IR) flanking the unique long (UL) and unique short (US)
portion of the viral genome. The IRs are essential for segment inversion during
recombination, which generates multiple isomers of the viral genome. VZV has two
isomeric forms, while HSV-1, HSV-2, and CMV have 4 isomeric forms. HHV-6A, HHV6B, HHV-7, EBV, and KSHV lack IRs that permit recombination and thus only exist as
one isomer.

Replication of Herpesviruses
The nine known Human Herpesviruses can replicate in various cell types
depending on their unique features. However, the replication cycle of these
Herpesviruses share several common features. During the course of lytic infection, the
viral envelope of Herpesviruses fuse with the cell’s plasma membrane and the
nucleocapsid releases the linear viral genome into the nucleus (Fig. 2) (1).
Subsequently the linear genome of Herpesviruses circularizes and initiates the
expression of the so-called immediate early genes.
3

Fig. 1. Genome organization of Human Herpesviruses. The unique (U), unique long
(UL), and unique short (US) coding region of the viral genome (solid lines) is flanked by
terminal (TR) and inverted repeats (IR) (box regions). The left direct repeat (DRL) and
right direct repeat (DRR) of HHV-6A, HHV-6B, and HHV-7 encode perfect (black box)
and imperfect (gray box) telomere TTAGGG repeats (1, 3, 4).
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Fig. 2. Schematic representation of lytic and latent replication of Herpesviruses.
During lytic infection, the HHV-6A and HHV-6B viral envelope fuses with the cell’s
plasma membrane through CD46R (24, 25). The nucleocapsid then enters the cell and
releases the linear viral genome into the nucleus (1). Subsequently, the genome of
Herpesvirus circularizes to form the viral episome and lytic or latent infection can
proceed. Lytic infection results in rolling-circle replication of the viral genome, cleavage
of concatemer, viral assembly, and egress. During latent infection, the genome
replicates as multiple copies of episomes in the absence of virion maturation. However,
the integration of HHV-6A and HHV-6B into the telomere of chromosomes during latency
will be further discussed in subsequent sections.
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The immediate early gene products activate the viral DNA polymerase and
replication of the viral genome occurs via rolling-circle mechanism (26, 27). Rollingcircle replication leads to the formation of concatemers consisting of linear viral genomes
linked in a head-to-tail conformation that are subsequently cleaved to give rise to single
copies of the complete viral genome. During the last late stage of the replication cycle,
various components of the virion are produced in large quantities, new virions are
formed, and the infected cell dies.

Maintenance of Latent Herpesviruses Genomes by Episomal Replication
However, not all infections lead to immediate production of mature virions.
Following primary infection, the genome of Herpesviruses can establish latency as a
nuclear circular episome (Fig. 2) (1, 26, 27). The expression of latent viral genes allows
the stable replication and persistence of the latent viral genome. During latency the
cellular DNA polymerase and latency-associated viral genes promote genome
replication of Herpesviruses without production of infectious virus, however the genomes
of HSV-1 and HSV-2 do not replicate during neuronal latency. Therefore, the central
dogma of Herpesvirus replication is that the viral genome establishes latency as a
nuclear circular episome and reactivation occurs through rolling-circle DNA replication
(1, 26, 27). However findings over the last two decades suggest this may not be the
case as pertaining to latency of HHV-6A and HHV-6B latency (28-34).
Luppi et al. identified the HHV-6 genome linked to a high molecular weight
cellular DNA in peripheral blood mononuclear (PBMCs) in three patients (34). The initial
observation of HHV-6 integration into the human genome was confirmed by other
laboratories (28-32); however the significance of this event, the location of viral
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integration, and whether the integrated viral genome reactivates from its integrated state
had not been fully characterized.
Results completed in this dissertation demonstrate the in vivo and in vitro
integration of HHV-6A and HHV-6B into the telomeres of human chromosomes during
latency (33). Moreover, HHV-6A and HHV-6B viral reactivation from its latent integrated
state was demonstrated in patient PBMCs and in vitro integrated cell lines. This
dissertation details the current knowledge of HHV-6 genome structure during latent
infections, the viral and cellular genes that could perhaps mediate integration, and lastly
discuss the cellular as well as the clinical impact of viral integration into the telomeres.

Integration of Herpesviruses and Retrotransposons into Chromosomes
Epstein-Barr Virus
During latency, the episomes of Herpesviruses associate with chromosomes
through the expression of viral DNA binding proteins such as EBV nuclear antigen-1
(EBNA-1) and KSHV’s latency-associated nuclear antigen (LANA) (35, 36). The binding
of EBNA1 and LANA to chromosomes is not site-specific, but this association of EBV
and KSHV episomes with chromosomes ensures each infected cell obtains multiple
copies of the viral episome during cell division. However, in rare cases as shown by
EBV, the full length genome infrequently integrates into random chromosome sites
during latency (37, 38). The integration of EBV into chromosomes has been
demonstrated during long-term passage of infected cell lines and the isolation of
reactivated virus from these cell lines has not been established.
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Marek’s Disease Virus
Similar to the integration of iHHV-6A and iHHV-6B into telomeres of human
chromosomes during latency (further discussed in subsequent sections) (33), the
Gammaherpesvirus Marek’s disease virus (MDV) frequently integrates into the telomere
of chickens through telomeric repeats (TTAGGG)n encoded in the internal repeat short
(IRS) of the viral genome (39-41). MDV is acquired through inhalation of virions
released from the dander of infected chickens. During latency, the linear ~180 kbp
dsDNA genome integrates into multiple telomeres of chickens in each cell. The
expression of viral oncogenes Meq and viral telomerase RNA (vTR) induces
transformation of T-cells and leads to the rapid formation of solid visceral tumors and Tcell lymphomas within two to six weeks.

Retrotransposon TRAS1
The sequence specific integration of the retrotransposable element TRAS1
(telomeric repeat-associated sequence) was found to frequently integrate within the
(TTAGG)n telomere repeat of the silkworm, Bombyx mori (42). The method of
integration occurs through cleavage of the telomere TTAGG sequence by the TRAS1
endonculease and the fusion with the TTAGG terminal repeats encoded in TRAS1 (43).
In summary, the specific integration of iHHV-6A and iHHV-6B into telomeres during
latency is a novel process for a Human Herpesvirus (33). However, the similar strategy
of telomere integration is also employed by the avian herpesvirus MDV and the silkworm
retrotransposon TRAS1 (39-43).
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Genome of Human Herpesvirus 6A and 6B
In particular, the viral genome of HHV-6B is 162 kbp long, containing 119 unique
open reading frames (ORF), while HHV-6A genome contains 119 unique ORF and is
159 kbp long (3, 4). The genomic architecture of HHV-6A and HHV-6B is organized into
two major regions (Fig. 1). The unique (U) region of the genome which is ~143 kbp,
contains seven major core gene blocks that are conserved amongst Herpesviruses.
These conserved genes are responsible for replication, cleavage, and packaging of the
viral genome into the capsid. Additionally, these viral genes include: DNA binding
protein, DNA polymerase, capsid, tegument, glycoproteins, and proteinase. Also, the U
region contains blocks of CMV related genes known as US22 family that are conserved
amongst Betaherpesviruses.
The second major genomic regions of HHV-6A and HHV-6B is the ~8 kbp left
and right direct repeats (DR) located at the termini of the U region (Fig. 1) (3, 4). Within
the right end direct repeat (DRR) and the left end direct repeat (DRL) the HHV-6A/HHV6B genome encodes a perfect TTAGGG telomere repeat array and an imperfect
TTAGGG repeat. The viral TTAGGG repeat sequence is conserved with the telomere
sequence of human chromosomes and also encoded within the DR of HHV-7 (44).
Details about this telomere repeat region will be further discussed in subsequent
sections.
The distinction between HHV-6A and HHV-6B can not only be classified by their
differences in clinical disease association, but also differences in their restriction
fragment length polymorphism and the nucleotide sequence of their genomes (3, 4, 33).
The nucleotide sequence identity between HHV-6A and HHV-6B is 90%. The variation
in nucleotide sequence is not only observed between HHV-6A and HHV-6B, but also
between clinical isolates and laboratory strains of the virus. Variability in the number of
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telomere repeats within the DR of clinical HHV-6A and HHV-6B isolates is observed in
the range of 15 to 180 repeats (33, 45). Furthermore, preliminary experiments suggest
that ORF U2 through U5 (46), as well as DR1 through the first exon of DR6 (47) are
dispensable for in vitro viral replication. These examples demonstrate the plasticity of
the HHV-6 genome as well as variability in the sequences of HHV-6A and HHV-6B
which warrant consideration for these viruses to be classified as different herpesvirus
species rather than merely a subtype distinction between “A” and “B” (48).

Pathologies and Unique Features of Human Herpesvirus 6B
Human Herpesvirus-6 (HHV-6) was initially recognized as Human BLymphotropic virus (HBLV) by Salahuddin et al. in 1986, given that the virus was
isolated from B-lymphocytes of patients infected with HIV, HTLV, and lymphoproliferative
disorders (2). However, through further molecular and clinical studies, as well as
sequencing of the viral genome, the virus was found to include two different species;
HHV-6A and HHV-6B (3-6). HHV-6A and HHV-6B have been shown to productively
infect T-lymphocytes, monocytes/macrophages, human umbilical cord blood, and
various cell lines (7-11).
Furthermore in 1988, Yamanishi et al. established that HHV-6B primary infection
in young children is the etiological agent of exanthema subitum (roseola infantum),
which is characterized by high fever, diarrhea, and a mild skin rash along the trunk,
neck, and face (5, 12). Serologic studies have found that by the age of two, 90 % of
children have acquired a primary HHV-6 infection due to a persistent level of HHV-6
DNA and antibodies detected in saliva (13, 14, 49). Few cases have also reported
severe complications such as febrile seizures, encephalitis, hepatitis, thrombocytopenia,
and hemophagocytic syndrome (12, 18, 50-52). Viral reactivation has also been shown
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to induce graft rejection in solid organ and bone marrow transplantation, seizures, and
encephalitis (6, 16-19, 53).

Pathologies and Unique Features of Human Herpesvirus 6A
The infection of multiple cell types by HHV-6B and HHV-6A occurs through
attachment to the complement regulator receptor CD46 (24, 25). The diverse cell
tropism and multiple disease associations with HHV-6A/HHV-6B are due, in part, to the
expression of CD46 present on the surface of all nucleated cells. In particular, HHV-6A
has been associated with several adult diseases; including cofactor in AIDS progression,
and various neurological disorders including encephalitis, ataxia, seizures, and chronic
fatigue syndrome (6, 15-23). However the causal link between human disease and virus
infection remains to be fully elucidated.
Results supporting HHV-6A as a co-factor in AIDS progression are based upon
several different lines of evidence. First, HHV-6A infection contributes to the killing of
CD-4 lymphocytes (11, 20, 54). Second, HHV-6A and HIV co-infection of the CD4
lymphocytes has shown to enhance HIV replication through activation of the long
terminal repeats (LTR) (21). However, the most compelling data was completed in a
study by Lusso et al. in which dual infection of macaques with HHV-6A and simian
immune virus (SIV) enhanced the progression to AIDS at a faster rate when compared
to those macaques infected with SIV alone (20).
Additionally, HHV-6A has a greater neurotropism when compared to HHV-6B
due to increased concentration of viral DNA present in the plaques of patients’ brains
with MS and its ability to establish latency in oligodendrocytes (6, 55-57). In particular,
Goodman et al. obtained biopsies from 5 patients brain tissue containing acute lesions
attributed to MS (56). In situ polymerase chain reaction detected HHV-6 DNA in
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oligodendrocytes, microglia, and lymphocytes, while immunocytochemical staining
identified viral antigens in microglia and astrocytes. Cermelli et al. utilized laser
microdissection to selectively isolate MS plaques from normal appearing white matter
(55). HHV-6 DNA was detected in 57.8 % of MS plaques and only in 15.9 % of normal
appearing white matter. However, 26.8 % of healthy brain tissue and 21.7 % of brain
tissue from patients with various neurological disease were positive for HHV-6, which
indicates that HHV-6 may normally reside in the brain (58).
Several investigators reported an increase in anti-HHV-6 IgG and IgM antibody
titers and HHV-6A DNA and RNA during clinical relapse of MS compared to controls (5961). HHV-6 DNA was also detected in the CSF and brain tissues at higher levels than
control individuals (55, 62). Interestingly, markers of HHV-6 infection increased during
relapse and decreased during remission (60, 63). In summary, these reports suggest
HHV-6A may have a role in MS progression; however the interpretation of these findings
remains uncertain.

Chromosome Integration of the Human Herpesvirus 6 Genome
Primary infection of HHV-6 leads to an increase in viral copies present in
peripheral blood of children and subsequent decrease in viral copies during latency (5,
12-14, 16). The genome of Herpesviruses forms a nuclear circular episome during
latency and the minimal amounts of viral genes are expressed to allow the stable
replication of the viral genome. However, in a select number of patients including adults
and children, there are high copies of HHV-6 genome consistently detected in peripheral
blood measuring greater than 1 million copies per ml or 1 copy of HHV-6 per cell (31, 33,
64, 65). Moreover, Jarrett et al. identified a patient with HHV-6 detected in multiple
tissues which is suggestive of germ-line transmission (66). In 1993 Luppi et al. identified
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a unique high molecular weight viral fragment present in PBMCs of three patients with
elevated copies of HHV-6 (34). This high molecular weight fragment resolved by pulse
field gel electrophoresis demonstrated one of the earliest observations of viral integration
into the genome. Subsequently, several other labs have shown integration of HHV-6
into human chromosomes through fluorescent in situ hybridization (FISH) and PCR
amplification allowed for the detection of HHV-6 sequences in hair follicles, lymph node,
spleen, kidney, brain, liver and cardiac tissues (28, 29, 31, 66, 67). The FISH assay
however, cannot distinguish non-covalent linkage of viral episomes from integration or
establish the specific site of viral integration.
Despite previous publications (28-32, 34, 64-66), investigators lacked conclusive
results supporting the integration of HHV-6 into chromosomes and whether the
integrated viral genome represented a latent infection remained unanswered. Therefore,
these questions will be addressed in subsequent sections.

Telomere Biology
The human telomere is a repetitive TTAGGG dsDNA sequence extended from
the end of chromosomes (Fig. 3) (68-70). The telomere repeat is bound by a set of
proteins that form the shelterin complex. TTAGGG repeat factor 1 (TRF1), TRF2, and
protection of telomeres 1 (Pot1) directly bind to the telomeric TTAGGG repeat. The
shelterin complex is then maintained through interaction with TRF1-Interacting Nuclear
Factor 2 (TIN2), TPP1 (TINT1, PIP1, PYOP1), and Repressor Activator Protein 1
(RAP1). Until recently, telomeres were believed to be transcriptionally silent; however
mammalian telomeres were shown to transcribe telomere-repeat-encoding RNA
(TERRA) (71). TERRA stabilizes the shelterin complex and facilitates telomere
heterochromatin formation through direct interaction with TRF1 and TRF2 (72).
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Therefore, the repetitive TTAGGG telomere sequence, shelterin complex, and TERRA
protect the ends of chromosomes from double stranded breaks, chromosome fusions,
and inhibit telomerase mediated lengthening (68-72).
The telomere length in somatic cells is 5-15 kbp and after every cell division,
250-300 bp are lost from the end of telomeres due to the challenges encountered with
the process of end replication (70). The Hayflick limit occurs when telomeres reach a
critical length, and cells undergo replicative senescence or apoptosis (73). Telomeres
can be lengthened by telomerase reverse transcriptase (TERT) through the addition of
the TTAGGG repeat (70). Telomerase mediated telomere lengthening has been
detected in germ-line cells, cancer cells, and stem cells (74).

Fig. 3. Diagram of the shelterin complex and TERRA maintenance of telomere
ends. The double stranded repetitive TTAGGG telomere sequence (black lines) is
bound by the TRF1 and TRF2, while the interaction of POT1 with the 3’ end of the
telomere promotes strand invasion of the telomere duplex-loop (not shown) (68-70).
TERRA (red line) stabilizes the shelterin complex and facilitates telomere
heterochromatin formation through the direct interaction with TRF1 and TRF2 (72).
Collectively, the shelterin complex inhibits telomerase mediated lengthening, double
stranded breaks, and chromosome fusions (68-72).
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Shay et al. estimated that 85 % of all malignant and transformed cells utilize
telomerase to lengthen their telomeres to prevent telomere attrition (74). However,
telomere length can also be maintained through the recombination mediated alternative
lengthening of telomeres (ALT) (75, 76). The mechanism of ALT has yet to be fully
characterized; however one method suggests that circular extrachromosomal telomeric
repeats (T-circle) formed from the lost of the telomere-loop (T-loop) at the end of
telomeres may serve as a template for telomere lengthening through rolling-circle
replication (77-80). Similar to the replication of T-loops, the circular episome of
herpesviruses also replicate through rolling-circle replication which leads to the formation
of viral concatemers (Fig. 2) (26, 27).
The integration of HHV-6A and HHV-6B into telomeres is a newly identified form
of human herpesvirus latency that will be discussed in this dissertation (33). The
knowledge attained from the virus telomere biology may play a critical role in
understanding the process of virus replication and integration.

Significance
HHV-6A and HHV-6B have been identified as cofactors in AIDS progression,
graft rejection in transplants, as well as associated with MS and various neurological
symptoms (6, 16-21, 53, 55-57). Furthermore, 90 % of the population has acquired a
primary HHV-6 infection by three years of age (13, 14). The prevalence of high HHV-6
viral load (106-107 copies per ml of blood) has been described in several British cohorts
(64, 65) attributed to chromosome integration of HHV-6. The prevalence of high viral
loads in normal blood donors was 0.8 % (4/500) (64) and 1.0 % (57/5638) (81) . In
contrast, prevalence of integrated HHV-6 in hospitalized patient cohorts was higher, 2.9
% (13/449) (64) and 3.3 % (6/184) (65). Therefore, it’s essential that investigators
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determine the overall clinical impact the integrated virus may have on hospitalized
patients and disease progression. As a result, the significance of this dissertation is the
characterization of the novel mechanism by which HHV-6A and HHV-6B integrates into
telomeres of human chromosomes during latency and the reactivation of the integrated
virus to lytic replication.
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OBJECTIVES

HYPOTHESIS: During Latency, the Human Herpesviruses 6A and 6B Genome
Integrates into the Telomeres of Human Chromosomes through Homologous
Recombination with the n(TTAGGG) Viral Repeats, and the Integrated Virus can
be Induced to Lytic Replication

AIM I. To Determine whether the Human Herpesviruses 6A and 6B Genome Integrates
into Chromosomes of in vitro Infected Cell Lines

AIM II. To Determine that Human Herpesviruses 6A and 6B Genome Integrates into the
Telomeres of Patients through Germ-Line Transmission

AIM III. To Determine if the Telomere Integrated Human Herpesviruses 6A and 6B
Genome can Reactivate from Latency and Produce Infectious Virus
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MATERIALS AND METHODS

Cell Lines, Primary Human T-cells, Media, and Virus Strains
Heparinized peripheral blood from four families with germ-line inherited HHV-6
(iHHV-6) was obtained by the HHV-6 Foundation (Table 11), after the subjects had
given informed consent. PBMCs were isolated by diluting peripheral blood with an equal
volume of RPMI-1640 and slowly pipetted onto isotonic density gradient of
Lymphoprep™ (Axis-Shield, Oslo, Norway). Since Lymphoprep™ has a density of
1.077 g/ml, mononuclear cells can be isolated from the interphase while erythrocytes
and granulocytes form a pellet (82). Samples were centrifuged for 30 min at 800 x g,
25°C. Mononuclear cells were isolated from the buffy coat located at interphase,
resuspended in RPMI-1640, and centrifuged for 10 min at 250 x g, 25°C. The pellet of
mononuclear cells was then resuspended in RPMI-1640 media containing 10 % FBS
and 5 μg/ml PHA (Sigma-Aldrich, St. Louis, MS) for 72 hrs followed by culturing in 100
U/μl IL-2 medium to promote the expansion of primary T-cells.
T-cell lines Jjhan (HHV-6 Foundation), Molt3 (ATCC), and Burkitt’s lymphoma
cell line Raji (ATCC) were maintained in RPMI-1640 complete medium containing 10%
FBS and 50 µg/ml gentamicin sulfate. Human embryonic kidney-293 cells (HEK-293)
were maintained in DMEM supplemented with 10 % FBS and 50 µg/ml gentamicin
sulfate. HHV-6A (U1102 strain) and HHV-6B (Z29 strain) viruses were supplied by P.
Pellett (Wayne State University). HHV-6 integrated Burkitt’s lymphoma cell line Katata
was supplied by M. Daibata (Kochi Medical School, Japan) (83).
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Human Herpesvirus-6 in vitro Integration and Infection of Cell Lines
To evaluate if HHV-6 frequently integrates in culture, we infected both T-cell lines
and HEK-293 cells (Table 2). To begin, HEK-293 cells cultured at 50 % confluency
were infected with HHV-6A (U1102) at 0.1 multiplicity of infection (MOI). The cultures
were incubated for five days. Then the cells were washed to remove extracellular virus,
and single cells were introduced in each well of a 96 well plate. Single HEK-293 cell
clones were expanded and genomic DNA was isolated through Wizard® Genomic DNA
Purification Kit (Promega, Madison, WI), while remaining cells were stored at -80 ºC in
10 % DMSO and FCS. To determine which clones were successfully infected with HHV6A, the presences of the viral genome was determined by PCR for ORF U94 (Table 6)
and agarose gel electrophoresis. Evaluation of in vitro HHV-6A integration was
competed by FISH with HHV-6 cosimd probes (Table 3) (84) and inverse-PCR coupled
with Southern blot hybridization (85).
Moreover, HHV-6A and HHV-6B infection and integration was evaluated in two
T-cell lines (Table 2). In these experiments, the T-cell line Jjhan was infected with HHV6A (U1102) and the T-cell line Molt3 was infected with HHV-6B (Z29). After removal of
dead cells through Lymphoprep™ isotonic density gradient, 107 T-cells were infected
with HHV-6A and HHV-6B at 1.0 MOI in 1 ml of RPMI-1640 complete for 2 hrs at 37°C.
Unabsorbed virus was removed by centrifugation for 5 min at 1,500 rpm, 25°C. Cell
pellet was resuspended to 106 cells/ml and incubated at 37 ºC, 5 % CO2. DNA was
prepared from cells at the peak of cytopathic effect (CPE) (5 – 14 days), containing ~103
infectious units/ml of virus. HHV-6A and HHV-6B viral integration into T-cell lines (Jjhan
and Molt3) were evaluated by amplification of the viral genome-telomere junction using
chromosome specific primers (Table 8). Southern blot hybridization and sequencing of
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pCR®4-TOPO® (TOPO TA Cloning® Kit for Sequencing, Invitrogen, Carlsbad, CA) clones
confirmed chromosome integration.
Table 2. HHV-6A and HHV-6B chromosome integrated cell lines.
Cell lines

Virus

Description

HEK-293

HHV-6A

Three single cell clones derived

Jjahn (T-cell)

HHV-6A

Mixed infection

Molt3 (T-cell)

HHV-6B

Mixed Infection

Katata [ref. (83)]

HHV-6B

EBVNegative Burkitt’s lymphoma

Immortalization of Human Herpesvirus 6 Integrated T-cells using Herpesvirus
saimiri
Immortalization of iHHV-6 positive patient T-cells (Table 12) with Herpesvirus
saimiri (HVS) strain 484-77 was used to generate lymphoidblastoid cell lines (LCL) (86,
87). A semi-confluent monolayer of owl monkey kidney (OMK) cells in a 100 mm-dish
was infected with about 106 pfu/ml (plaque forming units) of HVS strain 484-77. Once
OMK cells presented CPE (2 – 3 days), media was collected, and HVS virus present in
the supernatant was concentrated by high-speed centrifugation in a SW28 rotor for 1 hr
at 20,000 rpm. Human PBMCs were then harvested through Lymphoprep™ isotonic
density gradient followed by T-cell expansion through PHA and IL-2 stimulation. Patient
T-cells (2 x 107) were then infected with HVS and cultured in AIM V medium (Gibco)
supplemented with 20 U/ml IL-2. Lymphoidblastoid cell lines were achieved roughly
after 3 months in culture and these cell lines continuously divided in the absence of IL-2.

Reactivation of Chromosome Integrated Human Herpesvirus 6
Human PBMCs were either harvested through Lymphoprep™ isotonic density
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gradient or through incubating with RBC Lysis Solution (Bioworld Consulting
Laboratories, LLC) according to manufactures’ instructions. Reactivation of iHHV-6 was
then achieved through culturing 1x106 PBMCs per ml in RPMI-1640 medium
supplemented with 10 % FCS, 20 ng/ml TPA, and 1x10-6 M hydrocortisone or 80 ng/ml
TSA for 3 to 5 days. To isolate reactivated virus, 1x104 Molt-3 cells were added to 106
PBMCs and cultured for 10 – 14 days. Reactivation was monitored for cell CPE (cell
lysis and syncitia), Gardella gel, qPCR, and sequencing of ORF U94.

Isolation of Human Herpesvirus 6 Genomic DNA from Mammalian Cells
Isolation of cellular and iHHV-6 genomic DNA from mammalian cells began by
centrifuging 5 min at 500 x g, 4°C to pellet cell suspension. Supernatant was discarded
and cells were resuspended with 10 ml ice-cold PBS and centrifuged centrifuging 5 min
at 500 x g, 4°C. PBS resuspension and centrifugation was repeated for a second time to
remove any remaining contaminating material. Cell pellet was resuspended with 100 µl
PBS followed by the addition of 1.0 ml of lysis buffer and incubated for 12 – 18 hrs at
50°C. Lysis buffer contained 100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 25 mM EDTA (pH
8.0), 0.5 % SDS, and 0.1 mg/ml proteinase K. Genomic DNA was then extracted twice
with an equal volume of phenol and centrifuged 10 min at 1700 x g, room temperature
(RT). The aqueous phase was removed from the top layer and extracted with an equal
volume of chloroform/isoamyl alcohol (24:1) and centrifuged for 10 min at 1700 x g, RT.
The top aqueous phase was removed and DNA was precipitated by mixing 0.3 M
ammonium acetate, 2.5 volumes of ice-cold 96 % ethanol, and incubating 20 min at 80°C. Precipitated DNA was then centrifuged for 20 min at 4000 x g, 4°C. Next, pellet
was rinsed with 70 % ethanol, centrifuged for 5 min at 4000 x g, 4°C, and air dried for 10
– 20 min. DNA pellet was then dissolved in TE buffer and stored at 4°C.
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Alternatively, genomic DNA was isolated from whole blood and PBMCs with the
Wizard® Genomic DNA Purification Kit (Promega, Madison, WI) according to the
manufacture instructions. DNA concentration and purity was determined by agarose gel
electrophoresis compared to known concentration of λHindIII ladder or through
spectrophotometer analysis of A260:A280 absorbance ratio (NanoDrop
Spectrophotometer, ND-1000, Thermo Scientific, Wilmington, DE). DNA samples with
an A260:A280 ranges of 1.8 – 2.0 were utilized for downstream experiments.

Identifying Chromosome Integrated Human Herpesvirus 6
Gardella Gel Analysis
The vertical agarose gel technique of Gardella et al. is capable of distinguishing
cellular genomic DNA, covalently closed circular DNA (viral episomes), and replicating
linear viral DNA (Fig. 4) (88). This occurs through the gentle release of DNA by in situ
lysis within the loading well of the vertical agarose gel followed by the application of an
electric current. To begin, living lymphoid cells were first isolated from dead cells
through the isotonic density gradient of Lymphoprep™ (Axis-Shield, Oslo, Norway) as
previously described. Following, 1×106 cells were resuspended in 80 µl of sample buffer
(15 % Ficoll, 0.01 % bromophenol blue in TBE buffer) and could either be stored at 80°C or directly loaded into the wells of a 0.8 % vertical agarose gel. Cells were then
lysed in situ by layering with cell lysis solution (5 % Ficoll, 1 % SDS, 1 mg/ml pronase)
and electrophoresed 0.8 V/cm (22 V) for 3 hrs followed by 7.5 V/cm (70 V) for 14 hrs at
4°C in TBE buffer.
The DNA in the gel was visualized through ethidium bromide staining coupled
with the Gel Doc™ XR+ system equipped with a CCD camera (Universal Hood II, BioRad, Hercules, CA). Alternatively, to increase sensitivity, the gel was stained with 20 µl
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of SYBERGreen™ Nucleic Acid Stain (Lonza Rockland Inc., Rockland, ME) diluted in
200 ml of 1 X TBE buffer for one hour. The gel was then de-stained with 200 ml of 1 X
TBE for 30 min and the DNA is then visualized using the Molecular Dynamics STORM
Phosphor Imager (Model 860-PC, Amersham Biosciences, Piscataway, NJ). Next the
DNA was transferred to nitrocellulose and Southern hybridized with [α32P]-dATP labeled
HHV-6 cosmids and [γ32P]-ATP labeled mintochondrion oligonucleotides probes (Tables
3 and 4) (84, 85, 89).

Fig. 4. Diagram of vertical agarose gel of Gardella et al. (88). A suspension of 1 x
106 cells in sample buffer is loaded into the wells of a vertical agarose gel. Cells were
then lysed in situ by layering with cell lysis solution followed by the application of an
electric current. The high molecular weight cellular DNA is located in the loading well of
the gel, while covalently closed circular episomal DNA is in the middle of the gel and
linear viral DNA migrates at a faster rate toward the bottom of the gel.
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Table 3. HHV-6A cosmids utilized for synthesis of [α32P]-dATP probes (84).
HHV-6A (U1102) Cosmid

Sequence Location

PMF311-12

65 – 75 kbp

PMF335-6

50 – 72 kbp

Table 4. Oligonucleotides for [γ32P]-ATP labeled mitochondrion probes (89).
Oligonucleotide Name

Sequence

2R

5’-TGGACAACCAGCTATCACCA-3’

7F

5’-ACTAATTAATCCCCTGGCCC-3’

7R

5’-CCTGGGGTGGGTTTTGTATG-3’

13F

5’-TTTCCCCCTCTATTGATCCC-3’

13R

5’-GTGGCCTTGGTATGTGCTTT-3’

17F

5’-TCACTCTCACTGCCCAAGAA-3’

17R

5’-GGAGAATGGGGGATAGGTGT-3’

22F

5’-TGAAACTTCGGCTCACTCCT-3’

22R

5’-AGCTTTGGGTGCTAATGGTG-3’

Fluorescent in situ Hybridization
Patient PBMCs were stimulated for 72 hrs with PHA followed by the preparation
of metaphase chromosomes according to standard cytogenic protocol (90). Viral
integration was observed by HHV-6A (U1102 strain) pMF311-12 and PMF335-6 cosmid
(84) probes labeled with Fluorescein (Table 3). Subsequently, HHV-6 chromosomal
integration sites were hybridized with probes for the centromere of chromosome 17
(Vysis), BCL2 gene on chromosome 18 (Vysis), EWSR1 gene on chromosome 22
(Vysis), and telomere-PNA probe (DakoCytomation). DAPI was then used to visualize
metaphase chromosomes with Axiophot microscope (Zeiss, Austria). At least 11
metaphase spreads were examined per a sample.
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FISH experiments were performed in two independent laboratories (University of
Minnesota, Minneapolis, MN and the Children’s Cancer Research Institute, Vienna,
Austria). Each laboratory was blind to knowledge of the individual and family
membership from which each specimen had been obtained (Table 12).

CsCl/Ethidium Bromide Density Gradient
The CsCl/Ethidium bromide density gradient enables the segregation of
covalently closed circular DNA (cccDNA) from linear DNA. Cesium chloride (CsCl) (1.55
g/ml) and ethidium bromide (EtBr) (1 µg/ml final concentration) was added to DNA (50
µg) isolated from HEK-293 (Table 2) and family member T-cells with integrated iHHV-6
(Table 12). The volume and density of the gradient was adjusted with the addition of TE
and Cs/Cl to a final density of 1.55 g/ml as determined with the use of analytical balance
(Mettler, AE50). The samples were then centrifuged in a Beckman L7-75 (VTi65 rotor)
for 72 hrs at 45,000 rpm, 20°C. Following centrifugation, 200 µl fractions from the
gradient were collected in a 96-well plate. Aliquots from each fraction were then
analyzed by electrophoresis in a 0.8 % agarose gel running at 1.2 V/cm in TBE buffer.
The high density fractions of cccDNA and the lower density fraction of linear DNA were
combined in separate aliquots.
The linear DNA and cccDNA fractions were purified of ethidium bromide by
repeated extractions with 1 volume of isopropanol saturated with 5 M NaCl and
centrifugation for 3 min at 1500 x g, RT. The DNA from the lower aqueous phase was
then precipitated by mixing 1 volume of H2O and 2.5 volumes of 95 % ethanol, incubated
for 30 min at -80°C, and centrifuged for 30 min at 20,000 x g, 4°C. Remaining salts were
removed by washing with 70 % ethanol and the DNA pellet was then air dried to remove
trace amounts of ethanol followed by resuspension in 1 X TE buffer.
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To confirm the independent isolation of cccDNA and linear DNA, PCR with
REDTaq® DNA Polymerase (Sigma, St. Louis, MS) was utilized in combination with four
primer sets (Table 5). Isolation of linear DNA was confirmed with primers to cellular
encoded beta actin (91) and cccDNA fraction was confirmed by amplification of the
mitochondrion encoded cytochrome-C oxidase (92). The distinction between the
integrated genome of iHHV-6 from episome cccDNA fractions was determined through
amplification of ORF U94, while the HVS (strain C484) genome was detected using
primers to Stp oncogene.
Table 5. Oligonucleotides for CsCl/Ethidium bromide density gradient.
Oligonucleotide Name

Sequence

HVS C484 Stp-F

5’-CTCAGAACGCGGCAACAAACTTGA-3’

HVS C484 Stp-R

5’-TTTCGGCATACCTGGATCCCATGA-3’

Cytochrome-C oxidase-F [ref. (92)]

5’-TTCGCCGACCGTTGACTATT-3’

Cytochrome-C oxidase-R [ref. (92)]

5’-AAGATTATTACAAATGCATGGGC-3’

Beta actin-F [ref. (91)]

5’-CTGGAACGGTGAAGGTGACA-3’

Beta actin-R [ref. (91)]

5’-AAGGGACTTCCTGTAACAATGCA-3’

HHV-6 ORF U94-F

5’-ACAGCCATTCGATGGTTCCCAGAA-3’

HHV-6 ORF U94-R

5’-AACGAACTGGGAGACGTATGCGAT-3’

Agarose Gel Electrophoresis and Southern Blot Analysis
Agarose gel electrophoresis of DNA was carried out in 1 X TBE buffer (20 X
stock: 890 mM tris base, 890 mM boric acid, pH 8.0 HCl), staining with ethidium
bromide, and visualized with Gel Doc™ XR+ system equipped with a CCD camera
(Universal Hood II, Bio-Rad, Hercules, CA) . In preparation of Southern blotting (85), the
agarose gel was incubated and gently rocked twice for 15 min in the following solutions:
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1) 0.25 M HCl solution for DNA depurination; 2) 1 M NaCl, 0.5 M NaOH solution for DNA
denaturation; and 3) 1.5 M NaCl, 0.5 M Tris-HCl (pH 7.0) solution to neutralize.
The DNA from buffered agarose gels were transferred to supported nitrocellulose
or positively charged nylon membranes (Amersham Biosciences) through vacuumblotting (93). A solution of 1 X SSC (Saline-sodium citrate) diluted from a 20 X stock
buffer (3 M NaCL, 0.3 M sodium citrate, pH 7.0) was continuously applied to the top of
the agarose gel during the 30 – 45 min transfer. DNA was then immobilized to the
membrane by baking for 1 h in a vacuum oven at 80°C. Membranes were blocked for
nonspecific binding of the radiolabeled probes by incubating 10 ml of pre-hybridization
buffer [50 % formamide, 5 X SSC, 10 X Denhardt’s solution (0.2 % bovine serum
albumin, 0.2 % Ficoll 400, and 0.2 % polyvinylpyrrollidone), 0.5 mg/ml sonicated salmon
sperm DNA (or total E.coli DNA), 0.05 M Na3P04 (pH 6.5), and 0.1 % SDS] that had
been previously boiled for 5 min. During the 10 – 30 min incubation of membranes at
42°C with pre-hybridization buffer, [α32P]-dATP labeled vector DNA is added to 10 ml of
hybridization buffer [50% formamide, 5 X SSC, 1 X Denhardt’s solution, 0.1 mg/ml
sonicated salmon sperm DNA (or total E. coli DNA), 0.015 M Na3P04 (pH 6.5), and 0.1 %
SDS] and boiled for 5 min to denature the probe. Alternatively, [γ32P]-ATP labeled
oligonucleotide probes are added to room temperature hybridization buffer. Once prehybridization buffer is removed from the membrane, hybridization buffer with
radiolabeled probe is incubated for 16 – 18 hrs while rocking either at room temperature
for [γ32P]-ATP labeled oligonucleotides or 42°C for [α32P]-dATP random primer labeling.
The membrane is then washed with 3 – 4 times in a solution containing 0.1 X
SSC and 0.1 % SDS. The wash solution is either room temperature for [γ32P]-ATP or 55
– 60°C for [α32P]-dATP. Membranes were sealed in plastic wrap and exposed to a
Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CA) for 8 hrs – 14 days and
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analyzed using a Molecular Dynamics STORM Phosphor Imager (Model 860-PC,
Amersham Biosciences, Piscataway, NJ).

Synthesis of 32P-Radiolabeled DNA Probes
Oligonucleotide probes were first diluted to a final concentration of 10 ng/µl.
Next, oligonucleotides were then end-labeled with [γ32P]-ATP by adding 1.0 µl of 10 X T4
polynucleotide kinase buffer, 1.0 µl (10 U) of T4 kinase (Promega, Madison, WI), 7.0 µl
of [γ32P]-ATP isotope (PerkinElmer, Boston, MA), and 1.0 µl (10 ng/µl) oligonucleotide
that serves as the probe. The kinase reaction then proceeded for 30 min at 37°C. Then,
50 µl stop buffer consisting of 50 mM EDTA, 20 mM Tris-HCl (pH 7.5), 20 mM NaCl,
0.25 % dextran blue, and 1 % SDS was added. The radiolabeled oligonucleotide probes
were incubated at room temperature for 16 -18 hours with the DNA vacuum-blotted
membrane or stored at 4°C until use.
Synthesis of random primer [α32P]-dATP-radiolabeling of plasmid probes begins
by mixing 3 µl (20 - 100 ng) of plasmid and 3 µl of random primers (500 ng/µl) and
denatured for 3 min at 100°C. The microfuge tube is then immediately placed on ice for
5 – 10 min to allow annealing of random primers to the plasmid sequence. Incorporation
of [α32P]-ATP into plasmid sequence is achieved by adding 1.5 µl of 10 X DNA
polymerase buffer, 1.0 µl DNA polymerase I large fragment-Klenow (5 U) (Promega,
Madison, WI), 1.5 µl of 500 µM dNTP-ATP, 5.0 µl [α32P]-dATP isotope (PerkinElmer,
Boston, MA), and incubated at room temperature for 4 hrs. Then, 45 µl stop buffer is
added to the probe and unincorporated [α32P]-ATP is then removed by applying the
probe to a DNA cellulose column. The radiolabeled probe is either incubated at 42°C for
16 -18 hours with the DNA vacuum-blotted membrane or stored at 4°C.
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Quantitative Real-Time PCR (qPCR)
Patient T-cells positive for iHHV-6 and HHV-6A in vitro integrated HEK-293 cells
were treated for three days with TPA (20 ng/ml) and TSA (80 ng/ml) to see if reactivation
of the chromosome integrated virus leads to an increase in viral copies. To investigate
this, DNA was isolated from treated and untreated (control) cells and subjected to
quantitative real time PCR (qPCR) for HHV-6 encoded ORF U94 and normalized to the
house keeping gene beta actin. DNA samples were analyzed in triplicate and 10 fold
serial dilutions of U94-pZeoSV plasmid was used to generate a standard curve. For
negative controls, a no template control and genomic DNA from a HHV-6 negative cell
line was analyzed with every set. The master mix for each reaction contained: 100 ng
template DNA, 12.5 µl of Syber® Green JumpStart™ Taq ReadyMix™ for Quanitative
PCR (Sigma-Aldrich, St. Loius, MO), 0.25 µ internal reference dye, 1 µl of 5 µm stock of
forward and reverse primers for ORF U94 and beta actin (Table 6), and the volume was
increased to 25 µl with H2O.
Table 6. Oligonucleotides for quantitative real-time PCR.
Oligonucleotide Name

Sequence

Beta actin-F [ref. (91)]

5’-CTGGAACGGTGAAGGTGACA-3’

Beta actin-R [ref. (91)]

5’-AAGGGACTTCCTGTAACAATGCA-3’

HHV-6 ORF U94-F

5’-ACAGCCATTCGATGGTTCCCAGAA-3’

HHV-6 ORF U94-R

5’-AACGAACTGGGAGACGTATGCGAT-3’

The samples were then analyzed with Chromo4 Real-Time PCR Detector (BIO
RAD, DNAEngine) using the following thermocycling parameters: 94°C for 2 min, which
is the followed by 40 cycles of 94°C for 15 sec, 60°C for 1 min, and 72°C for 30 sec.
Next, a melt-curve ranging from 45°C to 90°C with 0.2 ºC increase every 2 sec was
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completed to ensure that fluorescence signal recorded by Syber® Green was the result
of the specific amplification of beta actin and ORF U94. Data was then analyzed with
DNA Engine Software. Fold change ratios of Ct values normalized to beta actin were
relative to untreated control. Statistical analysis was completed with the student T-test
and p < 0.05 was considered significant.

Cloning the Chromosome Integration Site of Human Herpesvirus 6
Inverse PCR
Inverse PCR (IPCR) amplification of the HHV-6 integration site was adapted from
Ochman et al. (94) (Fig. 5). Briefly, 2 μg of patient genomic DNA was restriction
digested with 10 U of MboI (Promega) for 14 hrs at 37°C. To allow monomeric
circularization and prevent ligation of several fragments, MboI-digested DNA was diluted
to 2 μg/ml, and ligated with 0.045 U/μl T4 DNA ligase (Promega) for 14 hrs at 15°C.
Amplification of 100 ng of ligated DNA was performed with primers IPCR-1 and IPCR-2
(Table 7) along with Expand 20 kbPLUS PCR System (Roche Diagnostics, Mannheim,
Germany). Identification of HHV-6 integration site was then achieved by agarose gel
electrophoresis and Southern hybridization with IPCR-probe to HHV-6 and telomere
repeat [γ32P]-ATP-radiolabeled oligonucleotides.
Table 7. Oligonucleotides for IPCR amplification and probe.
Oligonucleotide Name

Sequence

IPCR-1

5-’GCACAACCCACCCATGTGGTAGTCGCGG-3’

IPCR-2

5’-CGTGTGTACGCGTCCGTGGTAGAAACGCG-3’

IPCR-probe

5’-CTTACACTTGCCATGCTAGC-3’

Telomere repeat-probe

5’-TTAGGGTTAGGGTTAGGGTTAGGG-3’
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Fig. 5. Diagram illustrating the amplification of HHV-6-chromosome junction by
inverse-PCR (IPCR). Hypothesis: integration of HHV-6 occurs within the telomere of a
human chromosome via homologous recombination with the TTAGGG perfect repeats
within direct repeat right (DRR) (Fig. 1). IPCR involves digestion of genomic DNA with
MboI followed by self-circularization of HHV-6 DRR and adjacent chromosomal fragment.
PCR amplification of HHV-6-chromosome fragment is achieved through HHV-6 primers
IPCR-1 and IPCR-2. Co-hybridization with IPCR-probe and telomere probe via
Southern hybridization identified the HHV6-telomere-chromosome junction. DRL, direct
repeat left; U, unique.
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Chromosome-Specific PCR for iHHV-6 Integration
Both copies of the HHV-6 DR are bounded on their left by an imperfect TTAGGG
repeats and on their right by perfect arrays of the TTAGGG sequence. Thus, the right
end of the viral genome has a perfect TTAGGG array that derives from DRR and the left
end of the genome has an imperfect array that derives from DRL (3, 4). To amplify and
sequence the putative viral-chromosomal DNA junction, we created a primer pair
homologous to the DRL and DRR of the viral genome, as well as a primer to the
subtelomere of a specific chromosome (Fig. 6). The chromosome subtelomere primer
was selected based upon results from FISH of iHHV-6 (Fig.15).

Fig. 6. Strategy of chromosome-specific PCR for iHHV-6 integration. The putative
HHV-6-chromosome junction was amplified with a primer to the specific end of
chromosome subtelomere and the second primer derived from the (a) HHV-6 right direct
repeat (DRR) or (b) the left direct repeat (DRL). Both primers to DRR and DRL were
utilized since we were unaware whether iHHV-6 integration occurs via the left or right
telomere encoded repeats. Arrows indicate position of primers. Unique = U.
The PCR master mix for amplification of iHHV-6 integration site included: 400 ng
genomic DNA, HHV-6 DRR/DRL and chromosome specific primers (50 µM) (Table 8),
500 µM dNTPs, Expand 20 kbPLUS PCR system (Roche Diagnostics, Indianapolis, IN), 10
X taq buffer, and final volume was increased to 25 µl with H2O. Samples were placed in
a Peltier Thermal Cycler PCR (PTC-220, MJ Research Inc, Waltham, Ma) and subjected
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to the following PCR conditions: 94°C for 2 min, which is the followed by 35 cycles of
94°C for 10 sec, 64°C for 30 sec, and 68°C for 10 min, and finished with a final
extension of 68°C for 7 min.
Agarose gel electrophoresis and Southern blot hybridization with telomere, HHV6, and chromosome specific [γ32P]-ATP-radiolabeled oligonucleotide probes was utilized
for identifying DNA bands representing the putative viral-chromosomal DNA junction.
Specific bands were gel extracted with Perfectprep® Gel Cleanup Kit (Eppendorf,
Westbury, NY) and cloned with pCR®4-TOPO® (TOPO TA Cloning® Kit for Sequencing,
Invitrogen, Carlsbad, CA). A minimum of three clones from each sample was
sequenced by the Molecular Biology core facility at H. Lee Moffitt Cancer Center and
Research Institute.
Table 8. Oligonucleotides for chromosome-specific PCR and probe.
Oligonucleotide Name

Sequence

HHV-6 DRR

5’-CATAGATCGGGACTGCTTGAAAGCGC-3’

HHV-6 DRL

5’-CTTTCTCGCTGTGCCTCACGCTGTC-3’

Chromosome 11q primer (95)

5’-CAGACCTTGGAGGCACGGCCTTCG-3’

Chromosome 17p primer (95)

5’-AACATCGAATCCACGGATTGCTTTGTGTAC-3’

Chromosome 18q primer

5’-CTCATGTCCTCGGTCTCTTGCCTC-3’

Chromosome 17p probe (95)

5’-CCCAAGCAGGTTGAGAGGCTGAGG-3’

Generation of Recombinant Human Herpesvirus 6A BAC Virus Expressing GFP
and Neomycin Resistance
The generation of a recombinant HHV-6A (strain U1102) virus was accomplished
through the cloning of GFP expression cassette and neomycin resistance between the
two polyadenylation sites of ORF U53 and U54 (Fig. 7a). The pBeloBAC11 plasmid
(New England BioLabs, Ipswich, MA) with U53, U54, GFP, and neomycin resistance
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gene was transfected into HEK-293 cells. Cells were subsequently infected with wild
type HHV-6A (wt-HHV-6A) to enable homologous recombination between vector ORF
U53/U54 sequences with the genome of wt-HHV-6A (Fig. 8).
The method of cloning the targeting pBeloBAC11 vector began by PCR
amplification of ORF U53 (primers U53L and U53R) and ORF U54 (primers U54L and
U54R) from HHV-6A DNA prepared from infected cells with primers containing restriction
sites BamHI and SacII (Table 9). In addition, the GFP expression cassette driven by the
CMV immediate early gene promoter was amplified from pEGFP-N2 vector template (BD
Biosciences Clontech) with primers GFP-N2-L and GFP-N2-R. Next, the sub-cloning of
ORF U53, ORF U54, and GFP was completed in pBluescript SK+ (Invitrogen™ Life
Technologies™, Carlsbad, CA) followed by sequencing to confirm the absence of PCR
generated mutations.
Table 9. Oligonucleotides for generating Human Herpesvirus 6A BAC/GFP/Neor.
Oligonucleotide Name

Sequence

U53L

5'-GGCCCGCGGAGTAGTTCCGCGTCAGAATGC-3'

U53R

5'-GGCGGATCCCATTCGTTTTATTGAACGCG-3'

U54L

5'-GGCAAGCTTGCAATGGTTAAAAGTTGTTTTTTG-3'

U54R

5-'GCGCCGCGGCTGCATACTTGCTACCGGAAC-3'

GFP-N2-L

5'-CGCGGATCCATTAATAGTAATCAATTACGG-3'

GFP-N2-R

5'-CGCGGATCCCGCCTTAAGATACATTGATGAG-3'

The targeting vector was assembled by ligating fragments between the restriction
sites BamHI and HindIII of pBeloBAC11 with T4 DNA ligase (Promega, Madison, WI)
(Fig. 7b). Ligated products were then transfected into ElectroMAX™ DH10B™ E. coli
cells (Invitrogen™ Life Technologies™, Carlsbad, CA) through electroporation. The size
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and orientation of ORF U53, ORF U54, GFP, and neomycin resistance cloned within
pBeloBac11 was confirmed by restriction digestion and agarose gel electrophoresis.
Positive clones were selected with 30 µg/ml kanamycin and plasmid was purified
through QIAGEN® Plasmid Maxi Kit (QIAGEN Sciences, Germantown, MD) according
manufactures instructions. To further remove trace amounts of bacterial DNA, RNA, and
proteins, U53/U54/GFP/Neo-pBeloBAC11 was subjected to CsCl/ethidium bromide
density gradient.
To permit homologous recombination between U53/U54/GFP/Neo-pBeloBAC11
vector with ORF U53 and U54 encoded in the genome of wt-HHV-6A (Fig. 7b), the
vector was first linearized through digestion with SacII. Next, 5 µg of SacII digested
U53/U54/GFP/Neo-pBeloBAC11 was transfected in a 6-well dish of HEK-293 at 70 %
confluency with GenePORTER® Transfection Reagent (Genlantis, San Diego, CA) (Fig.
8). After 16 hrs post-transfection, HEK-293 cells were then infected with wt-HHV-6A
(U1102) at ~1.0 multiplicity of infection (MOI). Infected cultures were incubated for 5 –
12 days to allow homologous recombination with vector and insertion of GFP and
neomycin resistance gene into the HHV-6A genome (HHV-6AGFP). Since infected HEK293 cells contain both wt-HHV-6A and HHV-6AGFP, cells were lysed through sonication
or repeated freeze defrost cycles. HHV-6AGFP virus was then titrated out by infecting
Jjahn T-cell cultures with ~1 infectious unit per well in a 96 well plate. HHV-6AGFP was
expanded and progress of infection was monitored through GFP expression with Nikon
TE300 inverted microscope equipped with SPOT RT-SE6 1.4MP Slider camera
(Diagnostic Instrument. Inc.) and flow cytometric analysis.
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Fig. 7. Cloning of HHV-6A ORF U53 and U54 into pBeloBAC11 for generation of
recombinant HHV6AGFP. (a) Diagram of the HHV-6A genome with the location of ORF
U53 and U54 highlighted. The insertion of GFP/Neor/pBeloBAC11 occurs between the
polyadenylation sites of ORF U53/U54 to prevent interruption of transcription and/or
translation of those viral genes. (b) Vector map of U53/U54/GFP/Neo-pBeloBAC11.
The targeting vector was assembled by PCR amplify fragments of HHV-6A ORF
U53/U54, as well as GFP and Neor from pEGFP-N2 vector (BD Biosciences Clontech).
Fragments were then ligated between restriction sites BamHI and HindIII in pBeloBAC11
(New England BioLabs, Ipswich, MA). Restriction enzyme digestion of the SacII site
between ORF U53 and U54 linearizes the vector in preparation of homologous
recombination with HHV-6A genome (Fig. 8).
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Fig. 8. Strategy for construction of recombinant HHV-6A (U1102) virus expressing
GFP (HHV-6AGFP). As outlined in the scheme above, HHV-6AGFP was constructed by
homologous recombination between B/GFP vector (U53/U54/GFP/Neo-pBeloBAC11)
and the two polyadenylation signals of HHV-6A ORF U53 and U54 (85,981–86,034 bp)
Partial and 454-Deep Sequencing of Germ-Line Integrated Human Herpesvirus 6
Genome
iHHV-6 sequences from PMBCs (Table 12) were amplified with primers spanning
ORF U94 (fragment 141,267-143,197, primers U94L-1 and U94L-2; U94R-1 and U94R2) using 300 ng of genomic DNA with REDTaq DNA polymerase (Sigma-Aldrich) (Table
10). Cycling conditions were 95°C for 1 min, 66°C for 1 min, and then 72°C for 1.5 min
for a total of 24 cycles. Amplification of DR (fragment 421-1474, 151654-152707) with
primers DR-1 and DR-2 and cycling 95°C for 1 min, 53°C for 1 min, and 72°C 1.5 min for
a total of 24 cycles. DNA bands were isolated from 0.8 % agarose gel and cloned into
pCR®4-Topo® vector using the TOPO TA Cloning® Kit for Sequencing (Invitrogen,
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Carlsbad, CA). Clones (n=4) were then sequenced by the Molecular Biology core facility
at the H. Lee Moffitt Cancer Center and Research Institute.
454-sequencing of the iHHV-6A genome from Family-1/Sibling-2 was completed
in collaboration with Rolf Renne and the University of Florida Interdisciplinary Center for
Biotechnology Research.
Table 10. Oligonucleotides for amplifying and sequencing DR and ORF U94.
Direct Repeat (DR) (U1102 421-1474, 151654-152707) and ORF U94 (U1102 141267143197).
Oligonucleotide Name

Sequence

DR-1

5’-TGCCGCTTCAACTTCACCTT-3’

DR-2

5’-AGATGTGGAGAGAAACGCGA-3’

U94L-1

5’-TGTTCTTCTGCTAACTCGGACGCA-3’

U94L-2

5’-CAGTTCCAATGGGCGTGGACAAAT-3’

U94R-1

5’-ATCCACGCGTCTTCCGTGACTATT-3’

U94R-2

5’-TGTTCATGTCTTCCGGCGAAAGGT3-’

Single Telomere Length Analysis of iHHV-6
Various methods have quantified the overall length of a population of telomeres
(96). However, Baird et al. has established a protocol to calculate the length of a
telomere from a specific chromosome end (95, 97). The single telomere length analysis
(STELA) assay has successfully determined the length of telomeres from chromosomes
XpYp, 2p, 11q, 12q, 17p, and 18q with use of primers specific to individual chromosome
end. Therefore, we have adapted the STELA assay to determine whether the telomere
is extended beyond the left direct repeat (DRL) of iHHV-6A and iHHV-6B as well as
quantify the overall telomere length of the integrated chromosome (Fig. 9).
To begin, genomic DNA was isolated from iHHV-6A and iHHV-6B patients
PBMCs (Table 12) and HHV-6A in vitro integrated HEK-293 cells (Table 2) with Wizard®
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Genomic Purification Kit (Promega) or through proteinase-K digestion and
chloroform/isoamyl alcohol (24:1) purification. Next, the linker (Tellorette-2) containing a
single TTAGGG repeat was ligated to the end of the telomere by incubating 60 – 150 ng
of genomic DNA, 60 - 100 µM of oligonucleotide Telorette-2, and 4.5 U of T4 DNA ligase
for 13 hrs at 35°C. The ligation reaction was then purified through phenol
chloroform/isoamyl alcohol (24:1) and resuspended in 15 µl TE. Serial dilution of DNA
was amplified with a high fidelity taq polymerase (Expand 20 kbPLUS PCR System,
Roche), 25 µM linker annealing primer (Teltail-P1), 25 µM iHHV-6 primer (iHHV-6
STELA-P2) (Table 11). Cycling conditions were 92°C for 2 min, 27 cycles of 92°C for 15
sec, 59°C for 30 sec, 68°C 13.5min or 18 min, and a final extension of 68°C for 7 min.
Amplification products were separated through electrophoresis on a 0.8 % DNA agarose
gel and Southern hybridized with [γ32P]-ATP-radiolabeled telomere oligonucleotide probe
and PCR amplified (primers P3 + P4) HHV-6 DRL random primer [α32P]-dATPradiolabeled probe.
Telomere length of iHHV-6 integrated chromosome was then calculated based
upon the mean molecular weight of all bands co-hybridizing with telomere and HHV-6
DRL probes.

Fig. 9. Diagram illustrates the strategy of single telomere length analysis (STELA)
of iHHV-6. To amplify the specific chromosome telomere (Tel) extended beyond the
DRL of iHHV-6; a linker (Telorette-2) oligonucleotide is ligated to the end of the telomere.
Amplification of the telomere is then preceded with primers P1 and P2.
39

Table 11. Oligonucleotides for single telomere length analysis PCR and probe.
Oligonucleotide Name

Sequence

Tellorette-2 (Linker) (97)

5'-TGCTCCGTGCATCTGGCATCTAACCCT-3'

Teltail-P1 (97)

5'-TGCTCCGTGCATCTGGCATC-3'

iHHV-6 STELA-P2

5’-AAGGATGGTAGGGTTTAGGGTCGAACC-3'

iHHV-6 STELA-P3

5’-CCCTAACACTAATCCTCGCATCCGC-3’

iHHV-6 STELA-P4

5’-AAGGATGGTAGGGTTTAGGGTCGAACC-3’

40

RESULTS

AIM I. To Determine whether the Human Herpesvirus 6A and 6B Genome
Integrates into Chromosomes of in vitro Infected Cell Lines

Two Novel in vitro Models Demonstrate HHV-6A Chromosome Integration
Primary infection of HHV-6 leads to an increase in viral copies present in
peripheral blood of children and subsequent decrease in viral copies during latency (5,
13). However, in a select number of patients including adults and children, there are
high copies of HHV-6A and HHV-6B consistently detected in peripheral blood measuring
greater than 1 million per ml or 1 copy of HHV-6 per cell (31, 33, 64, 65). Through
further evaluation of these patients with FISH analysis, it has been suggested that the
genome of HHV-6 is integrated into the chromosome (28-32, 34, 98, 99). However, the
frequency of HHV-6 integration and whether integration is a product of infection remains
unknown. Therefore, in AIM I we developed two novel in vitro models of HHV-6A
integration to determine the frequency with which new infection of naïve cell lines with
HHV-6 leads to chromosomal integration, and whether this is the sole means by which
HHV-6 achieves latency.
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Single Cell Clones of Chromosome Integrated HHV-6A Human Embryonic
Kidney-293 Cell Lines
In our first model we set to determine if HHV-6A in vitro infection results in
chromosome integration. Since our preliminary experiments indicated that HEK-293
cells do not produce any appreciable amount of virus in cultures reaching full confluency,
we therefore expected this cell line to be a candidate to evaluate the in vitro integration
of HHV-6A (Table 2). We infected HEK-293 cells at 50 % confluency with HHV-6A
(U1102) at 0.1 multiplicity of infection (MOI). The cultures were incubated for five days.
Then the infected HEK-293 cells were washed to remove extracellular virus, and single
cells were introduced in each well of a 96 well plate. The single cells in each well were
then expanded and amongst these single cell clones, there were three populations. The
first population of single cell clones includes those that had reached cell senescence and
stopped dividing most likely due to virus infection. The second population of single cells
included those that expanded at normal rate as uninfected controls. However, the third
population of cells appeared to have ceased cell division, but then proceeded to divide at
a much slower rate than uninfected controls. DNA was then extracted from these single
cell clones and subjected to PCR for presence of the viral genome using ORF U94specific primers (Table 6) followed by agarose gel electrophoresis. As show in Figure
10a, 10 of the 22 HEK-293 cell clones were positive for ORF U94. This indicates the
successful infection and the presence of the HHV-6A genome within the HEK-293 single
cell clones.
To characterize the HEK-293 single cell clones for the presence of HHV-6A
integrated into chromosomes, FISH was completed at the University of Minnesota (Fig.
10b). Three PCR-positive clones (clone 1, 2, and 3) and one PCR-negative clone (clone
6) were studied for chromosome integration of HHV-6A by FISH. Metaphase
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Fig. 10. Detection of the viral genome by PCR and fluorescent in situ
hybridization (FISH) of HEK-293 cell clones latently infected with HHV-6A (U1102).
(a) Genomic DNA was isolated from HHV-6A infected HEK-293 cell clones.
Amplification of a 215 bp fragment representing ORF U94 was observed in five HHV-6A
infected HEK-293 single cell clones. (b) Representative FISH from three independent
HEK-293 cell clones. Hybridization was performed with HHV-6 cosmids pMF311-12 and
pMF335-631 labeled with fluorescein (green) (84). HEK-293/clone-1 had two
independent chromosome-associated HHV-6A signals, while HEK-293/clone-2 and
HEK-293/clone-3 only had one. The HHV-6A-hybridizing chromosomes are labeled with
white arrows and a higher magnification of the chromosomes are shown in red box.
Metaphase chromosomes were stained with DAPI. Total of 11 cells were observed for
each clone.
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chromosomes were obtained through culturing of the HEK-293 clones with colcemid
which effectively inhibits the formation of the spindle apparatus through interruption of
microtubules (90, 100). HHV-6A in vitro chromosome integration was observed by
fluorescein labeled HHV-6A (U1102 strain) pMF311-12 and PMF335-6 cosmid probes
and metaphase chromosomes were counterstained with DAPI (84). Analysis of HEK293/clone-2 and HEK-293/clone-3 identified one chromosome-associated HHV-6A
signal, while HEK-293/clone-1 had two independent chromosomes associated with the
HHV-6A genome (Fig. 10b). Furthermore, association of the HHV-6A genome with
chromosomes was identified at the termini of the long and short arm of chromosomes,
which is in proximity of the telomere
We could not identify the specific chromosomes into which HHV-6A had
integrated in the HEK-293 cells using standard cytogenetic methods. This was due to
the aneuploidy and chromosomal rearrangements present in these cells. Furthermore,
the FISH assay cannot distinguish the non-covalent linkage of ccc episomes from
chromosome integrated herpesviruses. Therefore, we studied the in vitro integration of
HHV-6A into HEK-293 single cell clones using inverse PCR (IPCR) (94). Genomic DNA
was first digested with the frequent cutter MboI, which cleaves methylated DNA. After
digestion and heat inactivation, we diluted the MboI digested DNA to 2 μg/ml, and ligated
with 0.045 U/μl T4 DNA ligase for 14 hrs at 15°C. The purpose of diluting digested DNA
was to prevent ligation of unrelated fragments and select for self-circularization of the
HHV-6A sequence with the adjacent chromosomal fragment. We next amplified the
ligated DNA using primers designed from the extreme right end (DRR) of the genome
(Table 8), which enabled amplification of the unknown chromosome sequence that is
fused with the viral genome (Fig. 30). Southern blotting identified IPCR products that
hybridized with a human telomere probe as well as an HHV-6 probe from the HHV-6A in
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vitro integrated HEK-293 single cell clones (Fig. 11). No hybridization was observed
without ligation of the MboI fragments. In summary, these experiments reveal that HHV6A can efficiently integrate into the telomeres of in vitro infected HEK-293 cells.

Fig. 11. Inverse PCR (IPCR) (94) analysis of DNA from HHV-6A in vitro infected
HEK-293 clones. Hypothesis: integration of HHV-6 occurs within the telomere of a
human chromosome via homologous recombination with the TTAGGG perfect repeats
within right direct repeat (DRR). Genomic DNA from HEK-293 clones 1, 2, 3, and 6 were
digested with MboI, diluted to prevent ligation of unrelated fragments, followed by selfcircularization of HHV-6 DRR with the adjacent chromosomal fragment. IPCR products
were analyzed by Southern blot hybridization with telomere oligonucleotide probe (left
panel), and with HHV-6 IPCR probe (right panel). Control IPCR was performed using
DNA without ligation (unligated) and hybridization controls HHV-6A infected Jjhan as
well as Jjhan (negative control).
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Recombinant HHV-6A BAC Virus Expressing GFP and Neomycin
Resistance
The use of bacterial artificial chromosomes (BAC) vectors to clone the entire
genome of herpesviruses has been instrumental in understanding the means by which
viruses replicate, while knockout-mutants have characterized viral proteins. To monitor
HHV-6A infection, we constructed an HHV-6A recombinant virus (HHV-6AGFP) carrying
the green fluorescent protein (GFP) and neomycin resistance (construction described in
Figs. 5 and 6). To accomplish this, we constructed a plasmid in which the GFP
expression cassette is flanked by 2 kbp fragments of ORF U53 and ORF U54 cloned
from HHV-6A strain U1102. Then we infected several human monolayer cell lines and
screened for those that supported lytic replication and in which transfection of the
plasmid was efficient. The most promising cell line was HEK-293 cells (101).
Preliminary experiments indicated that HEK-293 cells produce infectious virus at low cell
density/confluency. To generate HHV-6AGFP recombinants, a HEK-293 monolayer was
transfected with the ORF U53-GFP-ORF U54 BAC plasmid. The following day, cells
were seeded at about 10 % confluency and infected with 103 infectious units of HHV-6A
(U1102). After 6 days, we observed the characteristic cytopathic effect (ballooning,
refractile giant cells). The virus titer was determined to be 103 infectious units.
Since infected HEK-293 cells contain both wt-HHV-6A and HHV-6AGFP, the
potential recombinant virus was titrated out by infecting Jjhan T-cell cultures with about
one infectious unit per a well in a 96-well plate. In one culture, fluorescence microscopy
showed a dramatic increase in the number of green fluorescent Jjhan cells from 7 to 37
days post-infection (Fig. 12a). We observed only a few very bright fluorescent large
multinucleated cells, which were presumably producing infectious virus. However, the
majority of cells in the well displayed dimmer GFP expression.
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Fig. 12. Microscopic images and flow cytometry analysis of Jjhan cells infected
with recombinant GFP expressing HHV-6A (HHV-6AGFP). (a) Infection of Jjhan cells
resulted in an increase number of green fluorescent cells from 7 to 37 days postinfection as shown by fluorescent microscopy (100 X magnification). (b) Flow cytometry
analysis indicated that 60 % of Jjhan cells express GFP after 37 days post-infection with
HHV-6AGFP. (c) DNA from HHV-6AGFP and HHV-6A infected Jjhan cells as well as
uninfected Jjhan and Molt3 cells were isolated. PCR amplified ORF U53 with primers
U53L and U53R produced a 2033 bp amplicon in HHV-6A and HHV-6AGFP infected cells.

47

To analyze the distribution of infected Jjhan cells, flow cytometry was used to
examine the expression of GFP. Overall GFP expression in HHV-6AGFP infected Jjhan
cells was 60 % (Fig. 12b). To next evaluate whether GFP fluorescence corresponded to
production of HHV-6AGFP virions, we examined two hundred cells of the culture by
transmission electron microscopy (TEM) in the Fred Hutchinson Cancer Center EM core
laboratory for virus production. Even after examining two hundred cells, no virions were
observed. The viral DNA was reproducibly detected by PCR, indicating the presence of
the viral genome (Fig. 12c). However, despite several attempts, we detected no free
circular or linear viral genomes by the method of Gardella et al. (88). Therefore, the data
are consistent with the hypothesis that HHV-6AGFP established primarily latent infection
in Jjhan cells cultured for over one month, and that latency did not involve the formation
of viral episomes (Further evaluated in AIM 2 and AIM 3).
Previous attempts by other laboratories to generate an infectious HHV-6 BAC
cloned virus were unsuccessful (46, 102). However, we were the first laboratory to
successfully produce an infectious HHV-6A virus that expresses GFP and a selectable
marker (33). The reproducible cloning system was verified by Tang et al. in which they
utilized E. coli mutagenous techniques to investigate the replication dependence of
glycoprotein Q1 (103). The knowledge gained from the adaptation of recombinant HHV6 viruses focuses future studies to comprehend the clinical balance of viral infection,
latency/integration, and reactivation.

The in vitro Infection of Human T-cell Lines with HHV-6A and HHV-6B Results in
Telomere Integration
Since we have demonstrated the in vitro integration of HHV-6A into HEK-293, we
next wanted to determine if chromosome integration occurs in multiple cell types during
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infection. Specifically, we evaluated whether HHV-6A strain U1102 and HHV-6B strain
Z29 can integrate into the telomeres of the T-cell lines Jjhan and Molt3. These cells are
routinely used to propagate HHV-6A and HHV-6B, yet we observed that despite
supporting lytic infection, Jjhan and Molt3 cells often were not lysed and that many cells
survived after the peak of productive infection.
We hypothesized that in some of the infected cells, rather than productive
infection leading to cell lysis, the virus had achieved latency through telomere
integration. To examine this hypothesis, we prepared DNA from cells at the peak of
CPE, containing 103 infectious units/ml of virus. We then amplified the putative viral
genome-chromosome telomere junction using subtelomere based primers (2p, 11q, 17p,
and 18q) and a primer derived near the right end of HHV-6 DRR (95, 97). The primer to
DRR and not DRL was utilized because preliminary results determined that HHV-6A in
vivo integration occurs through the linkage of DRR with the telomere sequence directly
adjacent to the end of the chromosome, while the remaining telomere is fused with DRL
(Results further discussed in AIM 2, Figs. 19 and 23). Furthermore, the human genome
project has yet to fully sequence the ends of chromosomes due to their repetitive
sequence and homology shared with other subtelomeres. However, Baird et al. has
successfully sequenced the ends of chromosomes (subtelomere) and has utilized
primers 2p, 11q, and 17p to measure the length of telomeres of specific chromosomes
through PCR (95, 97). Consequently, Fig. 13 shows Southern hybridization of PCR
amplified viral genome-chromosome telomere junction from HHV-6B infected Molt3
cells.
To sequence the viral genome-telomere junction of HHV-6B/HHV-6A integrated
T-cell lines, we first cloned the PCR amplified fragments through pCR®4-TOPO® cloning
system (TOPO TA Cloning® Kit for Sequencing, Invitrogen, Carlsbad, CA). Following
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electrical transformation of E. coli One Shot® TOP10 (Invitrogen, Carlsbad, CA), positive
clones were identified by colony hybridization with [γ32P]-ATP-radiolabeled HHV-6 and
telomere oligonucleotide probes. Sequencing of clones confirmed the in vitro infection of
Jjhan cells results in the HHV-6A genome covalently linked with the telomere of
chromosomes 18q, 17p, and 11q (GenBank accession nos. GU784871 and GU784873)
(Fig. 14). Also, HHV-6B in vitro infection of Molt3 cells was found to integrate into
telomere of chromosomes 18q, 11q, and 2p. Therefore, the result of these experiments
are consistent with the possibility that shortly after in vitro infection of Jjahn, Molt3, and
HEK-293 cell lines, HHV-6A and HHV-6B can frequently integrate into the telomere
region of chromosomes.
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Fig. 13. PCR amplification of virus-chromosome telomere junction from HHV-6B
in vitro-infected Molt3 cells. DNA from HHV-6B (Z29) infected Molt3 cells were
subjected to amplification by PCR primers derived from HHV-6A DRR and subtelomere
primers 2p, 11q, 12q, and 17p published by Baird et al (95, 97). Subtelomere primer
18q was designed based upon GenBank sequence information. PCR products from
virus-chromosome telomere junction were separated by electrophoresis and analyzed by
Southern blot hybridization utilizing a 32P-labeled telomere oligonucleotide probe.
Multiple band sizes are due to the variable number of telomere repeats between the DRR
of HHV-6B and the chromosome (Fig. 14).
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>HHV-6A/Jjhan chromosome 11q integration
CAGACCTTGGAGGCACGGCCTTCGTTTGGGACAATTCGGGGCCGCATCGACGGTGAATAAAATCCTTCCTCTTTGCAGC
CCTGAATAATCAGGGTCAGAGATCAGTTAGGGTTAGGGTTAGGGTTAGGGTTGGGGTTGGGGTTGGGGTTGGGGTTGGG
GTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG
TTAGGGTTAGGGTTAGCCGGTGGTTTCCTTTGGCACCGTGCCAGGCGACCGTGGGTCCCAGACGGTGGCACGTCGCGCG
CGATGTCGTTTTGAATTGTCTTCACGTCTCACCCCGGTATGCCCCATCTACGTACCCACCCGCGACTACCACATGGGTG
GGTTGTGCGTGTCTGTGTGTCTGCGTGTGTACGCGTCCGTGGTAGAAACGCGGTGACAACGGATTACGGAGGTGAATGT
TGCGGTGGTTGGGACGGGGAGGGAGTGAAGAGATGTTTCCCGTATAGGTGTTTTTGGAACGTGGTTTTTTTTTCTTACA
CTTGCCATGCTAGCGATCGCCCTCTGTCTTCGGTCCGCGTTACCGTGTCGTGTGTACTTCCGCATACTTTTGTCTCTGC
GCCTCGATACACCCCGTTGATTGGATGATCGCCACATGTGTATTGGACGTCACAGTCTGCTATTTTTTTCACTGTCTAT
TTTTAAACCTGTTGTCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTTCTTATATTTTTCTGACGCTGTTCGTTTTC
TACGTTCGCCTCCAATCCCGGACGCACCTCCTTTGTATGTTCACTCCTCCCACCCCCCGGGGTGCCTATATAAGAAGCG
AACGCGACGCGCTTTCAAGCAGTCCCGATCATG
>HHV-6A/Jjhan chromosome 17p integration
TAACATCGAATCCACGGAATGCTTGTGTACTTGGAAACTTAACAATGTGGTCTACAAATCCACAAATAAGATACATTTT
TACATTTACTGGAAGTTTAATTCCTAAGTAATGTCTTATAATTTCCCTCATCTAAGTCTGTCGTTTCATTCCATTTATT
CGTAAGTATAATATTGCTATTGGTATTGTTTAAGGTAGAATTTTCATAATTTGGTGTAGAGATTATTCATTCCTAGCAT
ATACATATAAAATGGAATGTTTGGCCAGGCACCCGGGCTCATACCTGTAACCCAAGCAGGTTGAGAGGCTGAGGAAGGG
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGCCGGTGGTTTCCTTTGGCACCGTGCCAGGCGACCGTGGG
TCCCAGACGGTGGCACGTCGCGCGCGATGTCGTTTTGAATTGTCTTCACGTCTCACCCCGGTATGCCCCATCTACGTAC
CCACCCGCGACTACCACATGGGTGGGTTGTGCGTGTCTGTGTGTCTGCGTGTGTACGCGTCCGTGGTAGAAACGCGGTG
ACAACGGATTACGGAGGTGAATGTTGCGGTGGTTGGGACGGGGAGGGAGTGAAGAGATGTTTCCCGTATAGGTGTTTTG
GAACGTGGTTTTTTTTTTCTTACACTGCCATGCTAGCGATCGCCCTCTGTCTTCGGTCCGCGTTACCGTGTCGTGTGTA
CTTCCGCATACTTTTGTCTTGCGCCTCGATACACCCCGTTGATTAGATGATCGCCACATGTGTATTGGACGTCACAGTC
TGCTATTTTTTTCACTGTCTATTTTTAAACCTGTTGTCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTTCTATATT
TTTCTGACGCTGTTCGTTTTCTACGTTCGCCTCCAATCCCGGACGCACCTCCTTTGTATGTTCACTCCTCCCACCCCCC
GGGGTGCCTATATAAGAAGCGAACGCGACGCGCTTTCAAGCAGTCCCGATC
>HHV-6A/Jjhan chromosome 18q integration
CTCATGTCCTCGGTCTCTTGCCTCGGCAAAGATTAGATTAGGGTTAGGGTTTGGGTTCGGGTCAGGGTTAGGGTTAGGG
GTTGGGGTTAGGGTTCGGGTTAGGGTCAGGGTTTGGGTTAGGGTTAGGGTTA--------------------------GGGTTAGGGTTAGGGGTTGGGGTTAGGGTTCGGGTTAGGGTCAGGGTTTGGGTTAGGGTTAGGGTTAGGGTTAGGGTTA
GGGTTAGGGTTAGGGTTAGCCGGTGGTTTCCTTTGGCACCGTGCCAGGCGACCGTGGGTCCCAGACGGTGGCACGTCGC
GCGCGATGTCGTTTTGAATTGTCTTCACGTCTCACCCCGGTATGCCCCATCTACGTACCCACCCGCGACTACCACATGG
GTGGGTTGTGCGTGTCTGTGTGTCTGCGTGTGTACGCGTCCGTGGTAGAAACGCGGTGACAACGGATTACGGAGGTGAA
TGTTGCGGTGGTTGGGACGGGGAGGGAGTGAAGAGATGTTTCCCGTATAGGTGTTTTTGGAACGTGGTTTTTTTTTCTT
ACACTTGCCATGCTAGCGATCGCCCTCTGTCTTCGGTCCGCGTTACCGTGTCGTGTGTACTTCCGCATACTTTTGTCTC
TGCGCCTCGATACACCCCGTTGATTGGATGATCGCCACATGTGTATTGGACGTCACAGTCTGCTATTTTTTTCACTGTC
TATTTTTAAACCTGTTGTCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTTCTTATATTTTTCTGACGCTGTTCGTT
TTCTACGTTCGCCTCCAATCCCGGACGCACCTCCTTTGTATGTTCACTCCTCCCACCCCCCGGGGTGCCTATATAAGAA
GCGAACGCGACGCGCTTTCAAGCAGTCCCGATCTATG
>HHV-6B/Jjhan chromosome 2p integration
GAGCTGCGTTTTGCTGAGCACAGACCTGGGGGTCACCGTAAAGGTGGAGCAGCATTCCCCTAAGCACAGACGTTGGGGC
CACTGCCTGGCTTTGGGACAACTCGGGGCGCATCAACGGTGAATAAAATCTTTCCCGGTTGCAGCCGTGAATAATCAAG
GTCAGAGACCAGTTAGAGCGGTTCAGTGCGGAAAACGGGAAAGCAAAAGCCCCTCTGAATCCTGGGCAGCGAGATTCTC
CCAAGCTAAGGCGAGGGGCTGCATTAAAGGGTCCAGTTGCAGCATCGGAACGCAAATGCAGCATTCCTAATGCACACAT
GATACCCAAAATATAACACCCACGTTGCTCATGTGGTTAGGGTTAGGGTCAGGGTCGGGGTCGGGGTCGGGGTCAGGGT
CACGGTTAGGGGTTAAGTGTTAAGGGTTAGGGGTTAAGGGTTAGGGTTAGGGTAGGGTTAGG----------------AGGGTTAGGGTTAGGGTAGGGTTAGGGTTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTA
GGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAG
GGTTAGGGTTAGGGTTAGGGTTAGATTGCGCCAGCGGTTTCCCTTGGCGTCGTGCCAGGATAGCATGGGTCCGAGACGG
CGGCACGTCGCGCCCGATGCCGTTCCTCATTGTCTTCACATCTGCCCCCCGTATGCTCCCCGCCTGCCCACCCGCGACC
GCCATAGAGGTGGTGTGTGCGTGTCTGCGTGTCTGCGTGTGCACGCGTCTGTGGGAGAAACGCGGAGAAAAGGGATTAC
GGAGGGGGGTGTTGTGGTAGATGGGGTAGGGAGGGATGAAGGGATGTTTCCTTTGTTAGTATATTTCAGCGTTGTTTAT
TTTTTTTTCCTAGCTGCCATGCTAGGGGTCGGCCTTTGTCGTCGGTCCGCGTGACTGTCTGTCGCATGCACTTCCGTAT
ACTTTTTTTTTTTGCGCGCCGGCACGTCACGTCGATTGGATTGCTGCCACACGTGTATTCGATGGCATGGTCTCCTCTT
TTTTTTTTTCACTGTCTATCTCTGAACCTGTTATCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTCTTATTTTTTT
TACGCCGTTGATTTTCCGCGTTCGTCTCCAACCTCAGACCGACCTCGTGTGTATGTTGGCTCCTCCCACTCCCCGGGGC
GTCTATATAAAAGACGAATGTGGCGCGCTTTCAAGCAGTCCCGATCTATG
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>HHV-6B/Jjhan chromosome 11q integration
CAGACCTTGGAGGCACGGCCTTCGTTTGGGACAATTCGGGGCCGCATCGACGGTGAATAAAATCCTTCCTCTTTGCAGC
CCTGAATAATCAGGGTCAGAGATCAGTTAGGGTTAGGGTTGGGGTTGGGGTTGGGG----------------------AGGGTTTGGGTTGGGGTTGGGGTTGGGGTTGGGGTTGGGGTTGGGTTAGGGTTAGGGTTAGGGTTAGGTTAGGGTTAGG
GTTAGGGTTAGGGGTTAGGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAG
GGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGATTGCGCCAGCGGTTTCCCTTGGCGTCGTGC
CAGGATAGCATGGGTCCGAGACGGCGGCACGTCGCGCCCGATGCCGTTCCTCATTGTCTTCACATCTGCCCCCCGTATG
CTCCCCGCCTGCCCACCCGCGACTGCCATAGAGGTGGTGTGTGCGTGTCTGCGTGTCTGCGTGTGCACGCGTCTGTGGG
AGAAACGCGGAGAAAAGGGATTACGGAGGGGGGTGTTGTGGTAGATGGGGTAGGGAGGGATGAAGGGATGTTTCCTTTG
TTAGTATATTTCAGCGTTGTTTATTTTTTTTTCCTAGCTGCCATGCTAGGGGTCGGCCTTTGTCGTCGGTCCGCGTGAC
TGTCTGTCGCATGCACTTCCGTATACTTTTTTTTTTGCGCGCCGGCACGTCACGTCGATTGGATTGCTGCCACACGTGT
ATTCGATGGCATGGTCTCCTCTTTTTTTTTTTCACTGTCTATCTCTGAACCTGTTATCGTCTTCCCGCCAAGGCTATGT
GTCTCCGCCTTTCTTATTTTTTTTACGCCGTTGATTTTCCGCGTTCGTCTCCAACCTCAGACCGACCTCGTGTGTATGT
TGGCTCCTCCCACTCCCCGGGGTGTCTATATAAAAGACGAATGTGGCGCGCTTTCAAGCAGTCCCGATCTATG
>HHV-6B/Jjhan chromosome 18q integration
CTCATGTCCTCGGTCTCTTGCCTCGGCAAAGATTAGATTAGGGTTAGGGTTTGGGTTCGGGTCAGGGTTAGGGTTAGGG
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTCGGGTTCGGGTCAGGGTTAGGGTCAGGGTTAGGGTTAGGGTTAGGGT
TAGGGTT-----------------------------------------------------------------------AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTCGGGTTCGGGTCAGGGTTAGGGTCAGGGTTA
GGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTGGGTTAGG
GTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGATTGCGCCAGCGGTTTCCCTTGGCGTCGTGCCA
GGATAGCATGGGTCCGAGACGGCGGCACGTCGCGCCCGATGCCGTTCCTCATTGTCTTCACATCTGCCCCCCGTATGCT
CCCCGCCTGCCCACCCGCGACTGCCATAGAGGTGGTGTGTGCGTGTCTGCGTGTCTGCGTGTGCACGCGTCTGTGGGAG
AAACGCGGGGAAAAGGGATTACGGAGGGGGGTGTTGTGGTAGATGGGGTAGGGAGGGATGAAGGGATGTTTCCTTTGTT
AGTATATTTCAGCGTTGTTTATTTTTTTTTCCTAGCTGCCATGCTAGGGGTCGGCCTTTGTCGTCGGTCCGCGTGACTG
TCTGTCGCATGCACTTCCGTATACTTTTTTTTTTTGCGCGCCGGCACGTCACGTCGATTGGATTGCTGCCACACGTGTA
TTCGATGGCATGGTCTCCTCTTTTTTTTTTTTCACTGTCTATCTCTGAACCTGTTATCGTCTTCCCGCCAAGGCTATGT
GTCTCCGCCTTTCTTATTTTTTTTACGCCGTTGATTTTCCGCGTTCGTCTCCAACCTCAGACCGACCTCGTGTGTATGT
TGGCTCCTCCCACTCCCCGGGGTGTCTATATAAAAGACGAATGTGGCGCGCTTTCAAGCAGTCCCGATCTATG

Fig. 14. Sequencing of virus-chromosome telomere junction from HHV-6A
infected Jjhan cells and HHV-6B infected Molt3 cells. DNA from HHV-6A (U1102)
infected Jjhan cells and HHV-6B (Z29) infected Molt3 cells were subjected to
amplification by PCR primers derived from HHV-6A DRR and subtelomere primers 2p,
11q, and 17p published by Baird et al. (95, 97). Subtelomere primer 18q was designed
based upon GenBank sequence information. After cloning and sequencing of PCR
products data was subjected to GenBank nucleotide sequence analysis. Viruschromosome telomere junction is indicated: telomere TTAGGG repeats underlined and
bold, HHV-6 DRR text is red, and chromosome subtelomere text is blue.
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AIM II. To Determine that Human Herpesvirus 6A and 6B Genome Integrates into
the Telomeres of Patients through Germ-Line Transmission

The HHV-6A and HHV-6B Genome Integrates into Telomeres of in vivo Infected Tcells during Latency
Results from AIM 1 illustrate the in vitro infection of human T-cell lines as well as
HEK-293 cells with HHV-6A and HHV-6B results in the integration of the viral genome
into the telomere of chromosomes. Studies have also suggested that individuals can
harbor the HHV-6A or HHV-6B genome integrated into their chromosomes (28-31, 34,
98, 99) and may be vertically transmitted in the germ line (32). However, evidence of in
vivo integration is based primarily on fluorescent labeling of chromosomes with HHV-6
probes through FISH. This assay cannot distinguish non-covalent linkage of viral
episomes from chromosome integration and nor can establish the specific site of viral
integration. Therefore we sought to determine whether the in vivo integration of HHV-6A
and HHV-6B actually occurs and define the specific site of viral integration.
Several individuals were identified with neurological symptoms including CNS
dysfunction, ataxia, and chronic fatigue (Table 12). Family members of those individuals
also shared the same symptoms or were asymptomatic. A total of 13 patients from 4
different families living in various regions around the world were enrolled in this study.
Peripheral blood was isolated from each family member and quantitative real time PCR
identified more than one family member, including a parent and at least one child, had
an unusually high copy numbers of HHV-6 DNA. The copy numbers from individuals
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from 4 different families were at least one million copies of HHV-6 per ml of peripheral
blood (Table 12). However, Kondo et al. determined the copy number during the peak
of primary infection was only 637 ± 273 in 104 monocytes/macrophages and 115 ± 42 in
104 CD4+ T-cells (10). Therefore, the elevated copy numbers consistently detected in
patients of this study suggests chromosome integration of the viral genome.
To investigate the possibility that HHV-6A/HHV-6B had integrated into the family
members’ chromosomes, we first performed fluorescence in situ hybridization (FISH) on
T-cell cultures derived from peripheral blood. The experiments were performed in two
independent laboratories (University of Minnesota, Minneapolis, MN and Children’s
Cancer Research Institute, Vienna, Austria). Each laboratory was blind to knowledge of
the individual and family membership from which each specimen had been obtained. In
each experiment, HHV-6-specific fluorescence was detected in association with the
telomeric regions of chromosomes (Table 12 and Fig. 15). The specific chromosome
was identified by co-hybridization with viral and chromosome specific probes. HHV-6specific FISH signal was detected in chromosomes 17p13.3, 18q23, and 22q13.3, in the
three families studied with FISH. In each of these family members with integrated HHV6, the chromosome of integration was identical between both parent and children,
suggesting vertical transmission through the germ-line [inherited HHV-6 (iHHV-6)].
Furthermore, iHHV-6 and telomere FISH signals overlapped which signifies
chromosome integration occurs specifically at the telomere.
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TABLE 12. Patients from four independent families with chromosome integrated iHHV-6

Fig. 15. Fluorescent in situ hybridization (FISH) of metaphase chromosomes from
T-lymphocytes of family members. PBMCs were stimulated for 72 hrs with 20 ng/ml
PHA then cultured in RPMI 1640 medium containing 50 U/ml IL-2 and 10 % FCS.
Metaphase chromosomes were generated according to standard cytogenic protocol
(90), stained with DAPI and hybridized with various probes as follows; (a) FITCconjugated HHV-6A (U1102 strain) cosmid probes pMF311-2 and pMF335-6 (green)
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(84) and cy5-conjugated telomere peptide nucleic acid (PNA) probe (red)
(DakoCytomation). The viral genome was present in the same chromosome of the
corresponding parents and siblings suggesting germ line transmission (32, 33): Family-1
chromosome 18q23; Family-2 chromosome 17p13.3; and Family-3 chromosome
22q13.3. Lower right hand corner of each figure contains magnification of the
chromosome with integrated iHHV-6l DNA. (b) Representative FISH from members of
Families 1-3. Hybridization with FITC-conjugated HHV-6A (U1102 strain) cosmid probes
pMF311-2 and pMF335-6 (84). (c) cy5-conjugated BCL2 probe (Chromosome 18) (red),
FITC-conjugated chromosome 17 centromere probe (green), and cy5 and FITCconjugated EWSR1 probe (Chromosome 22) (dual labeled-red and green bottom row)
(Vysis).
To investigate whether the FISH method truly detects integration of iHHV-6 into
the chromosome of human telomeres rather than an association of the telomere with
episomal viral DNA, we analyzed T-cells from members of Family-1 with the method of
Gardella et al. (88). This method utilizes a vertical agarose gel capable of distinguishing
cellular genomic DNA from covalently closed circular DNA (episomes), and replicating
linear viral DNA (Fig. 4). This occurs through the gently release of the DNA by in situ
lysis of 1×106 PBMCs or T-cells within the loading well of the vertical agarose gel
followed by the application of an electric current. Southern hybridization with an HHV-6A
cosmid probe (84) confirmed the association of the viral genome with cellular DNA
located in the loading well of these gels (Fig. 16). No circular episomal and unit length
linear viral DNA was detected in these experiments which indicates that chromosome
integration is potentially a novel method in which a human herpesvirus can establish
latency. As a control, the blot was stripped and hybridized with a mitochondrion
oligonucleotide probe to illustrate successful cell lysis and separation of high molecular
weight mitochondrion DNA still remaining in the loading well from the circular and linear
forms.
To further validate the Gardella gel results, T-cells from member of Families 1, 2,
and 3 were immortalized using Herpesvirus saimiri (HVS) strain C484 and then applied
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Fig. 16. The vertical agarose gel technique identifies HHV-6 present in the host
genomic fraction of Family-1 T-cells. One million T-cells isolated from Family-1
members, control uninfected PBMCs, and HHV-6 positive Katata cell line (HHV-6B
integrated Burkitt’s lymphoma cell line) (83). Cells were loaded on a vertical agarose gel
and analyzed for episomal, linear, or integrated DNA by the method of Gardella et al.
(88). Southern hybridization with HHV-6A cosmid probe (Left panel) (84). Blot was
stripped and hybridized with mitochondrion oligonucleotide probe (Right panel) (89).
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Fig. 17. Analysis of HVS immortalized T-cells from iHHV-6 family members with
the vertical agarose gel technique. T-cells isolated from family members immortalized
with H. saimiri (HVS) strain C484 were subjected to vertical agarose gel technique of
Gardella et al. (88). Agarose gel was stained with ethidum bromide (left panel) and
southern hybridization with HHV-6A cosmid probe (middle panel) (84) illustrates viral
integration into the genome. Proper cell lysis and separation of linear and circular
fractions was evaluated by striping blot and hybridized with H. saimiri cosmid probe
(right panel) (86).
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to the Gardella gel. Southern hybridization with HHV-6A cosmid (84) probe detected
viral signal only within the genomic fraction (loading well) of the Gardella gel (Fig. 17),
which is consistent with results in Fig. 16. Hybridization of the same Southern blot with
HVS probe detected both circular episomal and replicating linear HVS DNA, confirming
proper release of herpesvirus DNA in the gel as well as the sensitivity of this assay (Fig.
17). Therefore, integration of iHHV-6 genome into the chromosome of Family-1, 2, and
3 members occurs during latency, while episome and replicating linear viral DNA was
not detected.
In Aim 1, we utilized Southern hybridization coupled with IPCR to establish that
HHV-6A in vitro integration of HEK-293 cells occurs at the telomeres (Fig. 11).
Likewise, IPCR experiments were also performed using DNA samples isolated from
PBMCs from members of Family-1. Briefly, genomic DNA was digested with the
frequent cutter MboI, which cleaves methylated DNA (Fig. 5). After digestion and heat
inactivation, we diluted the DNA to 2 μg/ml and incubated with T4-ligase for 16 hrs at
15°C. The purpose of diluting digested DNA was to prevent ligation of unrelated
fragments and select for self-circularization of the iHHV-6 sequence with the adjacent
chromosomal fragment. We next amplified the ligated DNA using primers designed from
the extreme right end (DRR) of the genome (Table 8), which enabled amplification of the
unknown chromosome sequence that is fused with the viral genome. Southern
hybridization of IPCR products were shown to hybridize with the HHV-6 and telomere
specific probe (Fig. 18). It is noteworthy that the IPCR products were identical in size
from iHHV-6A positive Family-1 members.
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Fig. 18. Inverse PCR (IPCR) analysis of iHHV-6A infected T-cells from Family-1.
Genomic DNA isolated from Family-1 T-cells were digested with MboI and diluted to
select for ligation of unrelated fragments. PCR amplification of HHV-6-chromosome
telomere fragments were then achieved through HHV-6 primers IPCR-1 and IPCR-2
(Table 7). Co-hybridization of HHV-6 IPCR (right panel) and telomere (left panel)
oligonucleotide probe via Southern hybridization detects viral integration into human
telomeres. Mother’s genome was negative control for IPCR (Table 12).
Covalent Linkage of the HHV-6 Genome with the Subtelomere of Chromosomes is
Mediated through the Viral Telomere Repeats Encoded in DRR
To build upon the experiments in the previous section, we next wanted to
definitely illustrate the in vivo integration of HHV-6A and HHV-6B into the telomeres of
chromosomes by directly amplifying and sequencing the site of integration. The HHV-6A
and HHV-6B genomes encode a perfect TTAGGG telomere repeat array at the right end
direct repeat (DRR) and an imperfect TTAGGG repeat at the end of left end direct repeat
62

(DRL) (Fig. 1) (3, 4, 104). We established a working hypothesis that HHV-6A and HHV6B integrates into telomeres via homologous recombination.
To amplify the putative viral-chromosomal DNA junction, we created a primer pair
homologous to the DRL and DRR of the viral genome, as well as a primer to the
subtelomere of chromosome 17p (Figs. 6 and 19a). The subtelomere is the
chromosomal region immediately adjacent to the TTAGGG telomere repeat array. T-cell
DNA isolated from Family-2 members were analyzed in these experiments since FISH
had identified the integration of HHV-6A into chromosome 17p13.3 (Fig. 15), and the
sequence of telomere-subtelomere junction of chromosome 17p is known (95).
Amplification with the primer pair designed from DRR and 17p subtelomere successfully
amplified the viral-cellular junction as determined by co-Southern hybridization with
HHV-6 DRR, telomere, and chromosome 17p oligonucleotide probes (Fig. 19b).
Furthermore, the absence of amplification with a primer derived from DRL confirmed the
integration of HHV-6A into human subtelomere is mediated through the perfect
TTAGGG found at the end of DRR.
To conclusively illustrate the HHV-6A DRR-subtelomere-chromosome junction,
the predominant 1.5 kbp amplicon was excised from the gel and cloned into pCR®4Topo® vector using the TOPO TA Cloning® Kit for Sequencing (Invitrogen, Carlsbad,
CA). E. coli One Shot® TOP10 (Invitrogen, Carlsbad, CA) was transformed through
electroporation and cultured with LB plates (30 µgl/ml kanamycin). Clones containing
the HHV-6A DRR-subtelomere-chromosome junction were determined through colony
hybridization with radiolabeled telomere, HHV-6, and chromosome 17p oligonucleotide
probes (Table 8). Plasmid DNA from positive clones was isolated with QIAprep® Spin
Miniprep Kit (Qiagen, MD) and Sanger sequencing was completed by the Molecular
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Fig. 19. Chromosome 17p subtelomere-specific PCR analysis of Family-2
members. (a) The putative HHV-6A-chromosome 17p junction. Arrows indicate
position of primers derived from the direct repeat left (DRL) and right (DRR) of the viral
genome (Unique = U) and to chromosome 17p subtelomere (95). (b) Genomic
DNA subjected to amplification: Family-2 Mother and Sibling, HHV-6A infected, and
uninfected Jjhan cells. PCR amplicons were separated by electrophoresis and analyzed
by Southern blotting using 32P-labelled oligonucleotide probes as indicated at the bottom
of each panel. Co-hybridization of a 1.5 kbp fragment with all three probes illustrates the
chromosome telomere joining with HHV-6A DRR. (c) The predominant 1.5 kbp amplicon
from Family-2/Mother was cloned (n=3) and sequenced. Genbank homology search
confirmed the presence of chromosome subtelomere 17p sequence (top) joined with
TTAGGG telomere repeats (red and underlined), and HHV-6A DRR sequence (bottom).
GenBank accession no. GU784872.
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Biology core facility at H. Lee Moffitt Cancer Center and Research Institute using T3 and
T7 primers. Sequencing results indentified the HHV-6A DRR covalently linked with the
subtelomere sequence of chromosome 17p from members of Family-2 (Fig. 19c). The
integration site contained 5 TTAGGG repeats, and integration resulted in the loss of 79
nucleotides from the far right end (DRR) the iHHV-6A genome (GenBank accession no.
GU784872). This observation is in agreement with other publications that have found
variability in the number of telomere repeats at the end of HHV-6 DRR and DRL (45, 99).

The Chromosome Telomere is Covalently Linked to the DRL of iHHV-6 Genome
Results in the previous section illustrate the telomere integration of iHHV-6
occurs through recombination with the perfect telomere repeats encoded in the DRR
(Fig. 19). Therefore, we sought to further characterize the genomic structure of iHHV-6.
Specifically, we wanted to determine if the DRL of iHHV-6 was conserved with the
integrated genome and whether the tandem array of telomere repeats [(TTAGGG)n] at
the end of the chromosomes was extend beyond the DRL (Fig. 20).

Fig. 20. Analysis of the genome conformation of chromosome integrated iHHV-6.
Results in Fig. 19 illustrate the DRR of iHHV-6 fused with the chromosome subtelomere.
However, it’s unknown whether homologous recombination occurs with the DRL (a)
perfect or (b) imperfect telomere repeats. Therefore there is a possibility the DRL could
be lost from the integrated genome during the process of integration.
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Experiments by Frenkel et al. has demonstrated the deletion of DR1 through the
first exon of DR6 from a laboratory strain of HHV-6A (U1102) was dispensable for in
vitro replication (47, 102). The deletion of DR was found during the process of cloning
the linear concatemer form of the virus during lytic replication. Therefore, we have
developed two PCR based assays to determine if the DRL of iHHV-6 was conserved with
the integrated genome of patients in this study (Table 12).
In the first experiment, the DRL was successfully amplified from Family-1
members’ genomic DNA (Fig. 21). Following Southern hybridization with telomere
specific oligonucleotide probe, we identified variability in the predicted molecular weight
of the amplified fragments. The variable number of telomere repeats between DR and U
has been previously characterized in clinical HHV-6 isolates (33, 45).
To confirm the results in the previous experiment, we evaluated the DRL in a
second group of patients with iHHV-6 and utilized a second primer set in combination
with restriction enzyme digestion (Fig. 22a). The PCR amplified DRL fragment has two
DraI restriction sites that lead to the expected fragment sizes of 1027, 217, 186 bp
according to the HHV-6A genome (strain U1102) (4). Similar to the results in Fig. 21,
the DRL was present in the iHHV-6 genome of all patients evaluated with PCR
amplification and DraI digestion (Fig. 22b).
Since we have illustrated the conservation of the DRL from iHHV-6, we next
wanted to determine whether the tandem array of telomere repeats [(TTAGGG)n] at the
end of the chromosome was extend beyond the DRL. Various methods have quantified
the overall length of a population of telomeres (96). However, Baird et al. has
established a protocol to calculate the length of a telomere from a specific chromosome
end (95, 97). The single telomere length analysis (STELA) assay has successfully
determined the length of telomeres from chromosomes XpYp, 2p, 11q, 12q, 17p, and
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Fig. 21. Amplification of the DRL from chromosome integrated iHHV-6. (a)
Diagram for the amplification of DRL in which primer 1 (P1) binds to region inside of DRL
and primer 2 (P2) binds within the U region of iHHV-6. (b) Amplification of DRL from
members of Family-1 results in the predicted size of 1,198 bp (HHV-6A U1102) as
shown in the ethidium bromide (Etbr) staining (left panel). Southern hybridization with
telomere oligonucleotide probe (right panel). Controls: HHV-6A (U1102) positive control
while Family-1/Mother and Jjhan were negative controls.
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Fig. 22. Amplification and restriction digestion of the DRL from chromosome
integrated iHHV-6. (a) Diagram for the amplification of DRL in which primer 3 (P3)
binds to region inside of DRL and primer 4 (P4) binds within the UL of iHHV-6. DraI
restriction sites are indicated by red arrows. (b) Amplification and restriction digestion
with DraI results in the predicted 1027, 217, 186 bp (HHV-6A U1102) as shown in the
ethidium bromide (Etbr) staining (left panel). Southern hybridization with HHV-6 DRL
oligonucleotide probe hybridizes with DRL 1027 bp band (right panel). Controls: HHV-6A
(U1102) positive control and Jjhan negtaive control.
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18q with use of primers specific to individual chromosome ends. Therefore, we have
adapted the STELA assay to determine whether the telomere is extended beyond the
left direct repeat (DRL) of iHHV-6A and iHHV-6B as well as quantify the overall telomere
length of the integrated chromosome (Fig. 20).
To begin, genomic DNA was isolated from iHHV-6A and iHHV-6B patients (Table
12) with Wizard® Genomic Purification Kit (Promega). Next, the linker (Tellorette-2)
containing a single TTAGGG repeat was ligated to the end of the telomere by incubating
60 – 150 ng of genomic DNA with T4 ligase for 13 hrs at 35C (Fig. 23a). The reaction
was then purified through phenonl chloroform/isoamyl alcohol (24:1) and resuspended in
TE. Serial dilution of linker-DNA was amplified with a high fidelity taq polymerase
(Expand 20 kbPLUS PCR System, Roche), linker annealing primer (Teltail-P1), and iHHV6 primer (P2) (Fig. 23a). The specific amplification of telomere sequences at the end of
DRL was indentified through southern hybridization with [γ32P]-ATP-radiolabeled
telomere oligonucleotide probe (Fig. 23bc).
To confirm the specific amplification of telomere sequences extended beyond
DRL of iHHV-6, the nitrocellulose blot was stripped and re-hybridized with PCR amplified
iHHV-6A DRL random primer [α32P]-dATP-radiolabeled probe. Co-hybridization of
telomere and DRL probes confirmed amplification of adjoining chromosome telomere
with the DRL of iHHV-6 (Fig. 20a). The heterogeneity of amplified telomere fragments
has also been previously observed in non-iHHV-6 integrated human somatic cells (95,
97). Furthermore, the specific telomere length of iHHV-6A integrated chromosome 17p
of Family-1/Sibling-2 PBMCs was 5,158 bp. This was calculated by determining the
mean molecular weight of all bands co-hybridizing with telomere and iHHV-6A DRL
radiolabeled probes from eight different PCR reactions.

69

Fig. 23. Single telomere length analysis of iHHV-6 integrated PBMCs. (a) Diagram
illustrating the strategy of single telomere length analysis (STELA) of iHHV-6. To amplify
the specific chromosome telomere (Tel) extended beyond the DRL of iHHV-6; a linker
(Telorette-2) oligonucleotide is ligated to the end of the telomere. Amplification of the
telomere is then preceded with primers P1 and P2. Serial dilution of (b) 150 ng and (c)
60 ng of DNA (EcoRI digested +/- for DNA solubilization) isolated from Family-1/Sibling2 (F1/S2) PBMCs was amplified with STELA primers. The specific telomere length of
iHHV-6A integrated chromosome 17p of Family-1/Sibling-2 PBMCs was 5,158 bp, while
the amplified range was 12,307 bp to 1,300 bp.
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HHV-6 Maintains its Latent Genome through Integration into Telomeres of
Chromosomes in the Absence of Covalently Closed Viral Episomes
Following infection, the genome of herpesviruses circularizes and the genome
replicates through rolling-circle replication facilitated by the viral DNA polymerase (26,
27). Replication leads to the formation of concatemers of linear viral genomes linked in
a head-to-tail conformation. The viral concatemer is subsequently cleaved to give rise to
single copies of the full length viral genome. However during latency, the genome of
herpesviruses remains as a nuclear circular episome, while the cellular DNA polymerase
and latency-associated viral genes promote replication of the viral genome without
formation of infectious virus (1, 26, 27). Moreover, the viral latency genes EBNA1 and
LANA promote the association of EBV and KSHV episomes with chromosomes via
protein-protein interactions (35, 36). This ensures each infected cell obtains multiple
copies of the viral episome during cell division. Therefore, the central dogma of
herpesvirus replication is that the viral genome establishes latency as a nuclear circular
episome and reactivation occurs through rolling-circle DNA replication (1, 26, 27).
We previously utilized the Gardella gel assay (88) to demonstrate the in vivo
integration of iHHV-6A into the chromosomes of members from Family-1 during latency
(Fig. 16). Furthermore, even after utilizing P32 radiolabeled HHV-6A cosmid probes (84),
the Gardella gel assay did not detect the presences of HHV-6 episomes. Therefore, we
looked for small numbers of episomes that might not have been detectable by the
Gardella gel assay (88).
Genomic DNA was isolated from HHV-6A integrated HEK-293 cells (Table 2),
and HVS immortalized iHHV-6A integrated T-cells from a member of Family-1 and 2
(Fig. 17). We next subjected these cells to CsCl/ethidium bromide gradient
ultracentrifugation to isolate the viral episome from the cccDNA fraction and the
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Fig. 24. PCR amplification fails to detect HHV-6 DNA in episomal fractions of
CsCl/ethidium bromide (EtBr) gradients. To search for covalently linked circular viral
episomes by a method more sensitive than the method of Gardella (88), 50 µg DNA from
two latently infected HEK-293 clones, T-cells from Family-2/Mother, and T-cells from
Family-1/Sibling-2 immortalized with HVS strain C484 were subjected to CsCl/EtBr
gradient ultracentrifugation for two days (CsCl density 1.55 g/ml, 10 µg/ml EtBr, VTI 65
rotor 40K rpm). After centrifugation fractions were collected, linear and episomal (ccc)
DNA identified by agarose electrophoresis. Salt and EtBr were removed from combined
linear and episomal ccc fractions and were subjected to PCR based amplification using
primers to (a) HHV-6 ORF-U94 and mitochondrial cytochrome c oxidase (positive
episomal control), (b) ORF U94 (HHV-6 genome) and beta actin (positive chromosome
control), and (c) HHV-6 ORF-U94, C484 (Stp), and cytochrome c oxidase (positive
episomal control). ccc stands for covalently closed circular episomal fraction.
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chromosome integrated iHHV-6A from the linear fraction. Fractions were subjected to
PCR amplification with primers to beta actin and cytochrome C oxidase (mitochondrion
genome) to identify the linear DNA and cccDNA fractions respectively (91, 92). PCR
amplification of ORF U94 (HHV-6) was then utilized to determine if the viral genome was
integrated or a circular episome during latency. Following CsCl/ethidium bromide
gradient and PCR amplification, iHHV-6 DNA was detected only in the linear fraction,
and was completely absent from the episomal (ccc) DNA fraction in both patient T-cells
and HEK-293 cells (Fig. 24ab).
Since our PCR assay can detect as few as 1-5 molecules, the CsCl/ethidium
bromide gradient ultracentrifugation experiment confirmed that the HHV-6 episome
cannot be detected even by a highly sensitive method. The amplification of
mitochondrial sequence in the linear fraction is expected since replicating and relaxed
mitochondrial episomes band together. Furthermore, the detection of HVS episomes in
immortalized iHHV-6A integrated T-cells demonstrate the sensitivity of this assay (Fig.
24c).

The Genome Sequence of Germ-Line Integrated HHV-6 from Patient T-cells is
Divergent from HHV-6A (strain U1102) and HHV-6B (strain Z29)
To investigate whether the iHHV-6 genome integrated in chromosomes of
Family-1 is the same among family members and to determine the degree of similarity to
HHV-6A (strain U1102) and HHV-6B (strain Z29), Southern hybridization of EcoRI
digested genomic DNA was performed (Fig. 25). Hybridization using a mixture of HHV6A (U1102 strain) cosmids (84) representing about 80% of the viral genome, revealed
that the banding pattern was indistinguishable among iHHV-6 positive members of
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Fig. 25. EcoRI restriction site analysis of integrated iHHV-6A in Family-1 T-cells.
Total genomic DNA was isolated from iHHV-6 integrated Family-1 members’ PBMCs,
HHV-6A (U1102 strain) infected Jjhan cells, HHV-6B (Z29 strain) infected Molt3 cells,
and uninfected PBMCs with Wizard Genomic DNA Purification Kit (Promega) according
to manufacturer’s protocol. 5 μg of genomic DNA was digested with 24 U of EcoRI
(Promega) and separated on 0.8% horizontal agarose gel. Southern hybridization was
completed with HHV-6A (U1102) cosmid (84) probe mixture.
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Family-1. However the pattern of the integrated viral DNA was significantly different
from prototype HHV-6A (U1102) or HHV-6B (Z29).
To evaluate the degree of variation between Family-1 and Family-2 integrated
iHHV-6 from the prototypical HHV-6A and HHV-6B strains, ORF U94 (141267-143197
bp) and DR (421-1474 bp, 151654-152707 bp) were amplified by PCR and cloned into
the pCR®4-TOPO® vector (Invitrogen). Sequencing was completed with primers T7 and
T3 by the Molecular Biology core facility at the H. Lee Moffitt Cancer Center and
Research Institute. The viral sequences from various family members were identical as
illustrated by the multiple sequence alignment (Fig. A1). However, the sequence DR
shared 96% identity with HHV-6A and 89% identity with HHV-6B (Table 12). DNA
sequences of the rep gene ORF U94 were more conserved; 98% identity with HHV-6A
and 95% identity with HHV-6B. It is noteworthy that chromosomal integrated iHHV-6
sequences obtained from Family-1 and Family-2 were more closely related to each other
than to HHV-6A and HHV-6B alone. Therefore, the similar viral sequences (Fig. A1 and
Table 12) and identical sites of chromosome integration (Fig. 15 and Table 12) between
family members confirms vertical transmission of the iHHV-6 genome through the germline.
In a study completed by Rapp et al.(105), sequences of the ORF U94 gene
shared remarkable conservation among isolates of HHV-6A (U1102 strain-99.4%
identity) and HHV-6B (Z29 strain-99.7% identity) among 17 isolates from three different
geographical locations. In contrast, our work has found only 98% sequence identity
between ORF U94 from the integrated iHHV-6 genome in two families (Table 12).
Since we have completed partial sequencing of the iHHV-6 genome (ORF U94
and DR), we now sought to determine the complete genome sequence of the reactivated
iHHV-6 (AIM 3) and compare the sequence to HHV-6A (strain U1102) and HHV-6B
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(strain Z29). To begin, genomic DNA was isolated from Family-1/Sibling-2 PBMCs and
454-Sequencing was completed in collaboration with the University of Florida
Interdisciplinary Center for Biotechnology Research. 454-Sequencing analyzed 156,609
bp of the iHHV-6 genome, which correlates to a genome coverage of 98.3%. Sequence
identity between the genome of iHHV-6 and HHV-6A (strain U1102) was 97.2%, while
only 88.3% sequence identity was shared with HHV-6B (strain Z29).
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AIM III. To Determine if the Chromosome Integrated Human Herpesvirus 6A
Genome can Reactivate from Latency and Produce Infectious Virus

TSA and TPA/Hydrocortisone can Induce Lytic Replication of Chromosome
Integrated HHV-6A
Experiments from AIM 1 and 2 provided substantial evidence that HHV-6A and
HHV-6B achieves latency via integration into the telomeres of human PBMCs in vivo and
following infection of T-cell lines and HEK-293 cells in vitro. It appears that in cell lines
capable of supporting productive, lytic infection, some of the cells also become latently
infected through chromosomal integration, and remain viable. Moreover, in neither the
in vivo or in vitro studies did we find HHV-6 DNA in episomal form—the strategy by
which other human herpesviruses achieve latency (Figs. 16, 17, and 24). Therefore, it
remained unknown whether iHHV-6 can reactivate from its integrated state to produce
infectious virions, making integration a molecular strategy for viral latency.
To determine if chromosomally-integrated HHV-6A and HHV-6B can reactivate,
we collected HHV-6A integrated HEK-293 cells and T-cells from five patients with iHHV6 (Table 2 and 12). These cells were cultured either in the presence trichostatin A
(TSA)—a histone deacetylase inhibitor known to reactivate latent herpesviruses—or with
12-O-Tetradecanoyl-13 acetate (TPA) and hydrocortisone for three days (106-110).
Genomic DNA was then isolated from these cells and the increase in viral copies was
determined by amplification of HHV-6 ORF U94 through quantitative real time PCR
(qPCR). TSA induced a 3.7 fold increase in viral copies for HEK-293 cells with
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integrated HHV-6A and 1.4 fold increase in viral copies from patient T-cells with iHHV-6
as compared to untreated control (Fig. 26). TPA and hydrocortisone produced similar
though milder effects.
To determine if the increase in viral DNA copies resulted in the production of
infectious virus, we cultured PBMCs from six members of Family-1 and Family-2 with
TPA and hydrocortisone. We then co-cultured these cells with Molt3 T-cell line in the
presence of TPA and hydrocortisone. After 2 weeks, lytic reactivation of iHHV-6 was
evident by observing syncytia in the infected Molt3 cells (Fig. 27).

Fig. 26. HHV-6 DNA qPCR analysis of patient T-cells and in vitro latently infected
HEK-293 cell lines induced by TPA and TSA. T-cell cultures from five family
members and three latently infected HEK-293/HHV-6A cell lines were cultured in AIM-V
or DMEM medium supplemented with 10% FCS and treated with 20 ng/ml TPA, 1x10-6
M hydrocortisone, and 80 ng/ml TSA for three days. DNA isolated from cells (in
triplicate) were subjected to quantitative real time PCR (qPCR) for ORF U94 and fold
change ratios of Ct values normalized to beta actin were relative to untreated control.
(a) HEK-293 (n=3) and (b) T-cells (n=5). TSA promoted significant increase in viral DNA
replication, while the stimulation with TPA and hydrocortisone had a milder effect.
Statistical analysis was based upon the student T-test and p < 0.05 was considered
significant.
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Fig. 27. Reactivation of iHHV-6A induces syncytium formation in a naïve T-cell
line. (a-d) Freshly isolated PBMC from Family-1/Sibling-2 stimulated with 20 ng/ml TPA
and 1x10-6 M hydrocortisone. PBMC were co-cultured with Molt3 cells for 2 weeks.
Syncytium formation (400X magnification) was documented. (e) Molt3 cells treated with
TPA and hydrocortisone and (f) Molt3 cells untreated.
To determine the stage of viral replication of iHHV-6A, we analyzed the
reactivated virus isolated from Family-1/Sibling-2 PBMCs through the Gardella gel (88).
Southern hybridization with HHV-6A cosmid probes demonstrated the lytic replication as
shown by the presence of replicating iHHV-6A linear DNA and RNA (Fig. 28).
Furthermore, sequencing of the DR region from latent chromosome-integrated iHHV-6A
(Family-1/Sibling-2) PBMCs was identical to the reactivated virus cultured in the Molt3
cells (Fig. A1). This confirms the successful reactivation of integrated iHHV-6 from
patient cells.
Taken together, the data suggest that HHV-6A and HHV-6B are unique among
human herpesviruses: they specifically and efficiently integrate into telomeres of
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chromosomes during latency rather than forming episomes—the strategy by which other
human herpesviruses achieve latency. Moreover, the integrated viral genome is capable
of reactivation to produce infectious virions. Thus, the integration of iHHV-6A and iHHV6B is not an unusual dead-end phenomenon, but a means of achieving latency.

Fig. 28. Analysis of in vitro reactivated iHHV-6A patient PBMCs with the vertical
agarose gel technique of Gardella et al. (88). Gardella gel analysis of infected Molt3
cells two weeks after co-culturing with PBMCs treated with TPA and hydrocortisone from
Family-1/Sibling-2. Hector 2 T-cell line carrying one copy of HHV-6A per a cell.
Reactivation was shown through linear DNA and RNA detected with HHV-6A cosmid
probe (84).
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During Reactivation, the Integrated iHHV-6 Genome Replicates via Formation of
Concatemers
Reactivation of the integrated iHHV-6A virus from individuals’ PBMCs as well as
cell lines was inducible after stimulation with TPA and TSA. Co-cultivation studies
indicated that the latent, integrated genome was capable of producing fully competent
virus. Reactivation of the integrated iHHV-6 resulted in the increase in viral copies
(Figs. 26 and 28) and induction of syncytium (Fig. 27). However, we set out to
determine whether reactivation of iHHV-6 genome resulted in rolling-circle replication
and the formation of concatemers and/or episomes of viral genomes similar to the
replication of other herpesviruses (1, 26, 27).
To reactivate HHV-6A (strain U1102) from latent integration, HEK-293 cells
(Table 2) were cultured with TSA at concentration of 160 ng/ml, 80 ng/ml, 40 ng/ml, 20
ng/ml, and 10 ng/ml for 3 days. Detection of viral episomes and/or concatemers was
completed by PCR amplification of the DR by two primers that annealed to either end of
the U region of HHV-6A (Fig. 29a). Thus amplification of DR would only occur during
circularization of the viral genome or concatemers of HHV-6A genomes linked in a headto-tail conformation (26, 27, 47, 102, 111, 112). Following co-hybridization with
telomere, DR, and U HHV-6A oligonucleotide probes, hybridization of DR specific
fragments was found in HHV-6A integrated HEK-293 cells treated with TSA (Fig. 29b).
Furthermore, DR specific signal was also detected in control HHV-6A lytic infected Jjahn
cells. We also identified variability in the molecular weight of the amplified DR
fragments. The amplification of multiple molecular weight bands is possibly due to
insertion of variable number of telomere repeats between DR and U during reactivation
mediated by homologous recombination. No hybridization was identified in either
control HEK-293 and untreated HEK-293/HHV-6A, which illustrates the in vitro
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reactivation of integrated HHV-6A is dependent on the histone deacetylase inhibitor
TSA.
In summary of AIM 3, reactivation of iHHV-6 genome after treatment with TSA
resulted in rolling-circle replication and the formation of viral concatemers add/or
episomes, which is similar to the replication strategy of herpesviruses (1, 26, 27).

Fig. 29. Reactivation of chromosome integrated HHV-6A from HEK-293 cells
induces episome and/or concatemer replication. (a) Schematic illustrating rollingcircle replication of herpesviruses results in concatemers of viral genomes (1, 26, 27).
Arrows indicate the location of primers utilized in the amplification of DR during lytic
infection. (b) HEK-293 cells with chromosome integrated HHV-6A (293/HHV-6A) and
HEK-293 cells (negative control) were culture with TSA at concentration of 160 ng/ml, 80
ng/ml, 40 ng/ml, 20 ng/ml, and 10 ng/ml for 3 days. DR amplification and Southern
hybridization with telomere, U, and DR oligonucleotide probes demonstrate rolling-circle
replication following TSA treatment. HHV-6A lytic infection of Jjhan cells (Positive
control). No amplification was detected in untreated 293/HHV-6A or 293 cells (Negative
controls).
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DISCUSSION

HHV-6A/HHV-6B Achieves Latency through Chromosomal/Telomere Integration
Overall, this study provides substantial evidence that HHV-6A and HHV-6B
establishes latency through an alternative mechanism differing from other human
herpesviruses (Fig. 30). HHV6-A and HHV-6B integrates into the telomeres of human
peripheral mononuclear cells in vivo (Figs. 15, 16, 17, 18, and 19), and following
infection in Jjhan T-cells, Molt3 T-cells, and HEK-293 cells in vitro (Figs. 10, 11, 12, 13,
and 14). It appears that in cell lines capable of supporting productive, lytic infection,
some of the cells quickly become latently infected through chromosomal integration, and
remain viable. Thus, HHV-6A and HHV-6B integration is not an unusual dead-end
phenomenon, but an alternative means of achieving latency.
Previous studies have used FISH to suggest that HHV-6 is capable of
chromosomal integration (28-32, 98). However, FISH cannot distinguish non-covalent
linkage from integration. In this dissertation, evidence that HHV-6A and HHV-6B can
integrate comes from multiple complementary methods besides FISH (Figs. 10 and 15):
chromosome-specific PCR (Figs. 13 and 19), sequencing (Figs. 14, 19, and A1) IPCR
(Figs. 11 and 18), Gardella gels (Figs. 16, 17, and 28), Cs/Cl Etbr ultracentrifugation
(Fig. 24), and two novel models (Figs. 10 and 12).
The results illustrate that iHHV-6A and iHHV-6B integrate into the host genome
via homologous recombination with human telomeres. In particular, telomere integration
of iHHV-6A and iHHV-6B occurs through recombination of the perfect telomere repeats
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encoded in the DRR juxtaposed to the end of the chromosome (Fig. 30c). Moreover, the
tandem array of telomere repeats [(TTAGGG)n] at the end of chromosomes was shown
to extend beyond the DRL of iHHV-6. Therefore, the structure of the iHHV-6 is as
follows: chromosome-subtelomere-(TTAGGG)5-41-DRR-U-DRL-(TTAGGG)n.

Fig. 30. Schematic comparing the genome structure of HHV-6 to germ-line
inherited HHV-6 (iHHV-6). (a) The linear HHV-6 genome contains a unique (U) region
of ~143 kbp with left and right direct repeats (DR) of ~8 kbp at the termini. Perfect and
imperfect telomere sequence (TTAGGG) positioned at end of DR play role HHV-6
chromosome integration into the telomere. (b) Fluorescence in situ hybridization (FISH)
of PBMCs from a patient with iHHV-6A integrated into the telomere of chromosome 22q.
Metaphase chromosomes counterstained with DAPI (blue), cy5-PNA telomere probe
(red), and FITC-conjugated HHV-6 cosmid probe (green). (c) Genome structure of
iHHV-6 in which HHV-6 DRR is fused with the telomere repeats near the chromosome
subtelomere and the DRL fused with the remaining telomere repeat array (TTAGGG)n
(33).
We also found that the latent integrated genome of iHHV-6A was inducible after
stimulation with TPA and TSA, and co-cultivation studies indicated that the latent,
integrated genome was capable of producing fully competent virus (Figs. 26, 27, and
28). During reactivation, iHHV-6 is excised from the integrated genome via homologous
recombination between flanking telomere sequences and generation of the DRR-DRL
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junction signifies circularization and concatemer formation through rolling-circle
replication (Fig. 29). Moreover, in neither the in vivo or in vitro studies did we find HHV6 DNA in episomal form—the strategy by which other Human Herpesviruses achieve
latency. Taken together, the data suggest that HHV-6A and HHV-6B are unique among
Human Herpesviruses: they have the potential to specifically and efficiently integrate into
telomeres of chromosomes during latency in the absence of circular episomes.

Reactivation of Chromosome Integrated HHV-6A/HHV-6B
The current understanding of HHV-6A and HHV-6B chromosome integration and
direct clinical link to disease is in its initial stages of development. Nevertheless, over
the last 20 years significant progress has been made. Considering the clinical
implications that iHHV-6 has when manifested into a patients’ DNA, it’s crucial to
determine whether reactivation of virus occurs from its latent integrated state. The first
experiment conducted by Daibata et al. induced lytic genes and capsid mRNA
expression from chromosomally integrated HHV-6 Burkitt’s lymphoma cell line through
culturing with the phorbol ester TPA (28).
Furthermore, results from AIM III demonstrate reactivation of iHHV-6A from
patient T-cells as well as viral integration amongst HEK-293 cells and T-cell lines in vitro
(33). Reactivation was achieved by means of co-culturing patient T-cells with the HDAC
inhibitor TSA or with TPA plus hydrocortisone. Reactivation of the integrated virus
induced increase in viral copies, while cytopathic effect was visibly evident by cell lysis
and syncytium formation in a naïve T-cell line (Figs. 26, 27, and 28). Moreover, partial
and 454 sequencing of the viral genome confirmed the iHHV-6A reactivation from its
latent integrated state (Fig. A1). This evidence further demonstrates that chromosome
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integration of iHHV-6 into telomeres is an alternative mechanism for a Human
Herpesvirus to establish latency, reactivates, and possibly induces disease.

Proposed Model for Latent HHV-6A/HHV-6B Chromosome Integration and
Reactivation
As previously discussed, integration of HHV-6A and HHV-6B into the telomeres
of chromosomes is unique and alterative means for a human herpesvirus to establish
latency (33). Comparable, the chicken hepresvirus MDV also integrates into the
telomeres of chromosomes during latency (39-41). However, the mechanism of MDV
integration differs from that of HHV-6A/HHV-6B as the genome of MDV integrates as
long concatemers. Furthermore iHHV-6A, iHHV-6B, and MDV can reactivate from their
latent integrated state to produce a lytic infection of naïve T-cells through chemicals
inducers (28, 33, 41). However, the mechanism of iHHV-6A, iHHV-6B, and MDV
telomere integration as well as reactivation remains to be fully elucidated.
In this next section, we propose a model (Fig. 31) to explain how the integration
of HHV-6A/HHV-6B into chromosome telomeres occurs during latency. The process of
integration emerges through homologous recombination between the viral and host
telomere repeats. During this process, we propose the binding of TRF1 and/or TRF2
proteins to the viral encoded TTAGGG repeats [similar to the binding of EBV Orip
TTAGGGTTA repeat (113, 114)]. This enables the linear HHV-6A/HHV-6B genome to
sit proximally to the chromosome telomere and permit homologous recombination.
Second, during the process of latency, ORF U94 may play a role in transcriptional
repression of lytic viral genes expression and aid in the specific integration of HHV-6 into
to the telomeres. Similar actions were observed in the rep68/78 mediated integration of
AAV-2 into chromosome 19q13.4 (115-117). Third, reactivation of iHHV-6 from its linear
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integrated state serves as a template for the replication of a linear dsDNA genome. The
induction of iHHV-6A, iHHV-6B, and MDV with HDAC inhibitors supports the notion that
reactivation precedes chromatin decondensation (Fig. 32) (28, 33, 41). This is followed
by circularization via recombination of the telomere sequences flanking the viral genome
and subsequent rolling-circle replication leads to concatemer formation of viral genomes
linked in a head-to-tail tandem conformation. Finally, cleavage of concatemers to unitlength viral genomes takes place during encapsidation of the viral DNA. Therefore
future studies need to determine if telomere proteins (TRF1 and TRF2) and TERRA
interact with the HHV-6A/HHV-6B encoded TTAGGG repeat and thus promote viral
integration into the telomeres.

Fig. 31. Proposed model for HHV-6A/HHV-6B integration into chromosome
telomeres. (A) We hypothesizes that localization of the linear HHV-6A/HHV-6B
genome to chromosome telomeres occurs through TRF2 and TRF1 bidding of
chromosome and HHV-6 DR encoded telomere repeat. (B) The viral rep gene ORF U94
then promotes homologous recombination between viral and chromosome telomere
repeats, (C) which results in the integration of HHV-6A/HHV-6B into chromosome
telomeres. The telomere integration event may also utilize alternative lengthening of
telomeres (ALT) for recombination.
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Fig. 32. Proposed model for iHHV-6 in vitro reactivation. (a) During latency, HHV6A and HHV-6B can integrate into the telomeres during in vivo and in vitro infection.
However, reactivation of iHHV-6 can be achieved through culturing of latently integrated
cells with TSA, or TPA plus hydrocortisone. (b) Reactivation of the integrated iHHV-6
results in genome replication through rolling-circle replication.
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It has been estimated that 85% of all malignant and transformed cells have
telomerase active in order to prevent telomere attrition (74). However, in those
remaining cells it is expected that telomere length is maintained through alternative
lengthening of telomeres (ALT) (75). The mechanism of ALT has yet to be fully
characterized; however one method suggests that circular extrachromosomal telomeric
repeats (T-circle) formed from the lost of the telomere-loop (T-loop) at the end of
telomeres may serve as a template for telomere lengthening through rolling-circle
replication (77-80). Similarly, herpesviruses replicate their genome through rolling-circle
replication to form a concatemer of linear viral genomes in a head-to-tail conformation
(1, 26, 27). Therefore, the telomere repeats found at the end of DRL and DRR of the
HHV-6A/HHV-6B genome may serve as an initial template for telomere elongation
through rolling-circle replication and thus allow the integration of the viral genome into
telomeres similar to the ALT pathway.

The Role of Human Herpesviruses Latency Genes in the Maintenance of the Latent
Viral Genome
KSHV: LANA and EBV: EBNA1
Latency genes expressed by Human Herpesviruses promote maintenance and
replication of the viral episome while inhibiting the expression of lytic genes (16).
Examples of Herpesviruses latency genes include EBV nuclear antigen-1 (EBNA-1) and
KSHV latency associated nuclear antigen (LANA) (35, 36). The Epstein-Barr virus
latency gene EBNA-1 was shown to bind to the origin of plasmid replication (OriP) of the
EBV encoded TTAGGGTTA repeat (imperfect telomere repeat) in cooperation with
telomere binding protein TRF2 binding (113, 114). TRF2 and EBNA-1 binding of OriP
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stabilizes the EBV episome during latency and enables the attachment of the EBV
genome to metaphase chromosomes through protein-protein interaction (36, 114).
Similarly, LANA binds within the KSHV terminal repeats (TR) to stabilize the viral
episome (118). Within the TR of KSHV, the transmembrane glycoprotein K1 promoter is
responsible for activating the signaling pathways for lytic infection (119). Therefore, the
binding of LANA to the TR suppresses both transcription of K1 and lytic replication. A
second target for LANA to establish latency is through inhibition of Rta, which is an IE
gene responsible for promoting lytic gene replication (120). Lan et al. established that
LANA has the ability to directly repress Rta’s promoter activity, and inhibit the autoactivation of viral transcription. Furthermore, the association of KSHV episome to
chromosomes is achieved by binding LANA’s C-terminus to the TR of KSHV and the N–
terminus to histones H2A-H2B (35, 121).

HHV-6: ORF U94
Currently, there are several lines of evidence suggesting that the unique gene
ORF U94 encoded by HHV-6A and HHV-6B may have a role in the establishment and
maintenance of latency. First, the expression of ORF U94 transcripts were observed in
latently infected PBMCs from healthy donors, while lytic viral transcripts were not
expressed (122). Second, lymphoid cell lines stably expressing ORF U94, were
permissive to HHV-6A infection, however no cytopathic effect was observed. There was
a steady decline in copies of viral DNA and transcripts detected 22 days post-infection.
Furthermore, the expression of ORF U94 decreased viral replication of
betaherpesviruses CMV and HHV-7 (123). Moreover, the ssDNA binding activity of ORF
U94 may have an impact on viral replication through transcriptional regulation (124).
This hypothesis is supported by studies that have shown ORF U94 to suppress H-ras
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mediated transformation in NIH3T3 cells and inhibit HIV-1 LTR expression at the level of
the promoter (125). The transcriptional regulation by ORF U94 was further verified by in
vivo and in vitro immunoprecipitation assay that indentified ORF U94 binding to the
human TATA-Binding Protein (hTBP) (126). hTBP functions as a subunit of the TATA
box binding transcription factor TFIID. This binding activity is a critical step for the
formation of the pre-initiation complex. Therefore, the transcriptional regulation of HHV6A/HHV-6B lytic genes could possibly occur through the interaction of ORF U94 with
hTBP and thus create a mechanism by which HHV-6A/HHV-6B can shift from a lytic to a
latent infection.
Interestingly, ORF U94 shares 24% sequence identity with latency gene
rep68/78, derived from the human adeno-associated virus type 2 (AAV-2) (127).
Rep68/78 regulates viral gene expression and directs the site specific integration of
AAV-2 into the AAVS1 site in chromosome 19q13.4 (115-117, 128). The function of
rep68/78 is through DNA binding, endonuclease, and helicase activities. Furthermore, in
a rep68/78 deficient AAV-2 model, the virus no longer integrates into the chromosome
(129). However, the expression of ORF U94 was able to complement the activity of
rep68/78 and rescue the mutant AAV-2 virus to replicate and integrate. Therefore, this
suggests that ORF U94 may function as a latency gene and possibly facilitate HHV6A/HHV-6B specific integration into telomeres similar to its AAV-2 encoded rep68/78
counterpart.
Despite the fact that the 490 amino acids of ORF U94 shares only 24%
sequence identity with rep68/78 (127), there are structural features that may exhibit
similar biological functions (Fig. 33). The ORF U94 C-terminus (residues 229-490 aa)
corresponds to the helicase and ATPase domain of rep68/78. Specifically, the
sequence codes for Walker A and B motifs that form the core of the class SF3 helicase
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Fig. 33. Structural SWISS-MODEL and consensus sequence of HHV-6A ORF U94
N and C-terminus. (a) The predicted ribbon diagrams of the U94 N-terminus (15-206
aa) corresponds to the AAV rep nuclease domain [Protein Data Bank (PDB) accession
number 1uut (128)). (b) The C-terminus (229-490 aa) of ORF U94 corresponds to the
AAV rep helicase domain [PDB accession number 1s9h (130)] circled in blue. (c)
Consensus protein sequence of AAV-2 Rep78 illustrates the DNA-binding domain (DBD)
and endonuclease (Endo) domain for the N-terminus of HHV-6A ORF U94. (d) The
consensus protein sequence of AAV-2 Rep40 helicase domain and C-terminus of HHV6A U94. The Walker (A, B, B’, and C) motifs form the core of the SF3 helicase and the
arginine (Arg) finger catalyzes ATP hydrolysis when the protein forms a hexamer
structure.

92

active site and an arginine finger which is critical player in ATP hydrolysis (130).
Furthermore, the N-terminus (15-206 aa) of ORF U94 corresponds to the DNA binding
and endonuclease domain of rep68/78 (128). It has been found that the N-terminus of
ORF U94 has ssDNA-binding activity (124) and the endonuclease domain of rep68/78 is
required for the site specific cleavage of the AAVS1 site which is shared by both the
inverted terminal repeats of AAV-2 and chromosome 19q13.4 (128). In conclusion, the
structural features shared between ORF U94 and rep68/78 emphasizes the importance
of elucidating the function of this protein and implications it may have on viral replication,
integration, and latency.

Possible Impact of HHV-6A/HHV-6B Integration on Telomere and Chromosome
Stability
Theoretically, the ability of HHV-6A and HHV-6B to integrate into the genome
could alter the stability of individual chromosomes and the expression of adjacent
subtelomeric genes. Interestingly, subtelomeric rearrangement and deletions of
chromosomes has been associated with mental retardation (131). In a review of 1,718
patients with mental retardation from 14 studies, 97 patients (5.8%) had subtelomeric
rearrangements or deletions (132). In particular, terminal deletion or subtelomere
rearrangements of chromosome 17p13.3 PAFAH1B1 gene results in Miller-Dieker
syndrome which is characterized by mental retardation, lissencephaly, growth
deficiency, seizures, and facial abnormalities (133, 134). de Grouchy syndrome is
characterized by mental retardation, growth deficiencies, and hearing loss due to
deletion of chromosome region 18q23 (133). Moreover, genetic mapping of patients
with bipolar disorders has identified a deletion at chromosome 18q23, however the link
remains controversial and the specific locus has not been identified (135, 136). In
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conclusion, iHHV-6A and iHHV-6B integration into chromosomes 17p13.3, 18q23, and
22q13.3 (Table 12) warrants direct sequencing and further cytogenetic analysis for
chromosome deletions and rearrangements during integration.
Potentially, the integration of iHHV-6A and iHHV-6B into the telomere of
chromosomes could alter the expression of adjacent subtelomeric genes through the
inhibition of telomere position effect (TPE) (137). TPE is characterized by transcriptional
repression of telomere adjacent genes through the recruitment of HDAC and histone
H3K9 methylation emanating from the constitutive heterochromatin state of the telomere.
The epigenetic regulation of TPE is well characterized in Saccharomyces cerevisiae
(137-140). The use of reporter systems (GFP, luciferase, URA3) has identified TPE in
excess of 20 kbp downstream of the telomere sequence in S. cerevisiae. However less
established in human cells, Baur et al. observed a 10 fold decrease in the expression of
telomere adjacent luciferase reporter when compared to reporter that was integrated
near the centromere (141). Moreover, the heterochromatin state of TPE was reversible
after treatment of human cells with TSA. This resulted in the suppression of HDACs and
transcriptional activation of the luciferase reporter, which is similar to the TSA mediated
reactivation of iHHV-6A and iHHV-6B from its latent integrated state (Figs. 26, 27, 28,
29, and 32). Therefore, further experiments are needed to determine if TPE plays a role
in suppressing iHHV-6A and iHHV-6B lytic genes during latency, and whether the
integrated viral genome alters the expression of nearby genes due to interruption of
TPE.
These findings might also have relevance for telomerase activity. Mammalian
and yeast chromosomes express a telomeric repeat-containing noncoding RNA
(TERRA) (142). TERRA is proposed to regulate telomerase and many important
telomere functions (142), and TERRA transcription is initiated in the subtelomere (Fig.
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34a). Therefore, it’s possible that telomere integration of HHV-6A/HHV-6B could alter
the expression of TERRA leading to dysfunction of telomerase or telomere chromatin
decondensation (Fig. 34bc).
The integration of HHV-6A and HHV-6B into telomeres is a newly identified form
of human herpesvirus latency and the knowledge attained from the virus telomere
biology may play a critical role in understanding the process of virus replication and
integration. The length of telomeres in somatic cells is 5-15 kbp and after every cell
division, 250-300 bp are lost from the end of telomeres due to the challenges
encountered with the process of end replication (70). Cells reach the Hayflick limit once
their telomeres reach a critical length, and undergo replicative senescence or apoptosis.

Fig. 34. TERRA expression and the possible impact of HHV-6A/HHV-6B telomere
integration. (a) The expression of the TERRA transcript is initiated in the chromosome
subtelomere. Alternatively, it’s unclear if HHV-6 integration alters TERRA expression.
(b) It possible that TERRA expression could be initiated in the DRR or DRL of HHV-6 or
(c) the transcript is produced across the genome of HHV-6.
Alternatively, telomeres can be lengthened by telomerase reverse transcriptase
(TERT) through the addition of the TTAGGG repeat (70). Telomerase mediated
telomere lengthening has been detected in germ-line cells, cancer cells, and stem cells.
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The repetitive telomere sequence and the complex of six telomere associated proteins
protect the ends of chromosomes from double stranded breaks, chromosome fusions,
and inhibits telomerase mediated lengthening (68, 69). The complex of telomere
associate proteins known as the shelterin complex contains: TRF1 (TTAGGG Repeat
Factor 1), TRF2 (TTAGGG Repeat Factor 2), and Pot1 (Protection of Telomeres 1)
directly bind to the telomeric TTAGGG repeat. The complex protein interaction of the
shelterin complex is maintained through TIN2 (TRF1-Interacting Nuclear Factor 2), TPP1
(TINT1, PIP1, PYOP1), and RAP1 (Repressor Activator Protein 1). In turn, TERRA
stabilizes the shelterin complex and facilitates telomere heterochromatin formation
through the direct interaction with TRF1 and TRF2 (72).
From the six shelterin proteins, TRF2 was shown to bind to the three nonamer
EBV encoded TTAGGGTTA repeat (imperfect TTAGGG repeat) within the origin of
plasmid replication (OriP) in cooperation with viral latency gene EBNA-1 (113, 114).
TRF2 and EBNA-1 binding of OriP stabilizes the EBV episome during latency and
enables the association of the viral genome to metaphase chromosomes (36, 114). This
mechanism ensures division of the EBV genome amongst daughter cells during mitosis.
Moreover, Lieberman et al. also found that EBNA-1 directly interacted with TERRA,
however the principle of this interaction has not been fully elucidated (72). Similarly, we
hypothesize that the binding of telomere repeats encoded in the DR of HHV-6A and
HHV-6B by TRF2/TRF1 plays a role in telomere mediated integration by facilitating the
localization of the viral genome to the telomere of chromosomes (Fig. 31). This in turn
promotes homologous recombination of the viral telomere repeats and that of the
chromosome telomere.
The integration of iHHV-6A and iHHV-6B into the same chromosome telomeres
of family members lends itself to vertical transmission through the germ-line (Table 12)
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(32, 33, 143). Moreover, studies have shown that iHHV-6A and iHHV-6B preferentially
integrates into telomeres of chromosomes 9q34.4, 17p13.3, 18q23, 19q13.4, and
22q13.3 (28, 29, 32, 33, 144). These results may be explained by three different
mechanisms. First, a number of chromosome ends may be more accessible for
homologous recombination between the viral and chromosomal TTAGGG repeats due to
heterochromatin structure of the chromosome telomere. Alternatively, HHV-6A/HHV-6B
may integrate randomly into all 92 telomere regions at the end of chromosomes, but the
integrated genome may be unstable in some telomeres (33). After a series of cell
divisions, it’s possible that cells with unstable chromosomes would be “negatively”
selected over those with stable chromosomes. Finally, telomere integration could have
occurred as a single event and thus inheritance of the genome occurs through multiple
generations.
Results thus far have shown that between in vivo integrated iHHV-6 amongst
patients and in vitro integrated cell lines, the viral DRR of the genome is integrated within
5 - 41 telomere repeats from the end of the chromosome (Figs. 14, 19, and 30) (33).
The proximity of the ~160 kbp iHHV-6 genome integrated between the end of the
chromosome and tandem array of telomere repeats suggests that the virus has a
minimal impact on the telomere/shelterin complex. However, if the iHHV-6 genome was
to integrate near the end of the telomere, one would expect progressive shortening of
the telomere leading to loss of sequences from the viral genome. Subsequently, this
loss may lead to chromosome instability as the result of chromosome fusion, replicative
senescence, or the inability of the shelterin complex to bind the non-telomere coding
sequence of the virus to form the cap at the end of telomere.
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Transmission of iHHV-6A/iHHV-6B via the Germ-Line
Following primary infection, HHV-6A/HHV-6B establishes a latent infection
primarily within monocytes/macrophages and in the salivary gland (10, 16). It is believed
that the predominant means of acquiring HHV-6A/HHV-6B is the result of horizontal
transmission through viral shedding from the saliva of infected individuals to uninfected
infants and children. However, vertical transmission of inherited HHV-6 (iHHV-6)
through the germ-line has proven to be a novel mechanism by which the virus integrates
during latency. Daibata et al. described the first reported case of iHHV-6 vertical
transmission through the germ-line of parent to their child (145). This initial observation
was confirmed by several other laboratories (32, 33, 98, 143). In each of these reports,
both parents and children with iHHV-6 contained identical sites of chromosome
integration (Table 12 and Fig. 15). Furthermore, the same virus strain of iHHV-6 was
inherited through the germ-line between parent and child. This was evident because
iHHV-6 integrated in each family member contained similar restriction fragment
polymorphism profiles and similar sequence of select viral genes (Fig. 25, Table 12, and
Fig. A1) (33).
Additional evidence supporting vertical transmission of the iHHV-6 genome was
described in a study showing cases of HHV-6 congenital infection obtained through
germ-line transmission or transplacental infection of the fetus (98). It was reported that
from a total of 254 infants enrolled in a study, 16.9% (43/254) had acquired a congenital
HHV-6 infection and 16.5% (42/254) acquired HHV-6 through primary infection by 36
months. Furthermore, the majority of congenital HHV-6 was acquired through germ-line
in which, 14.6% (37/254) infants were positive for iHHV-6 and only 2.4% (6/254) had
acquired HHV-6 through transplacental infection. Furthermore, germ-line transmission
results in viral integration within the chromosome of every cell that resides in the
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individual. This statement coincides with the information previously describing the viral
load of patients consistently detected at or above 1 copy per cell (32, 33, 98, 143).
Frequently observed in hematopoietic stem cell transplant patients, HHV-6 may
reactivate and induce graft rejection, bone marrow suppression, and encephalitis (1, 16,
22). Moreover, even after ablation of the recipient’s bone marrow in preparation for
transplantation, it has been shown that the donor stem cells may transfer iHHV-6 to the
recipient (144, 146, 147). This results in the subsequent rise of HHV-6 viral copies
within the recipient peripheral blood as well as introduction of iHHV-6 positive stem cells.
Investigations are also necessary to understand how immunosuppressive agents used
to prevent graft rejection affect iHHV-6 infected patients. Will clinicians also have to
consider screening for iHHHV-6 during blood donations? The initial studies on the
transmission of integrated iHHV-6 into chromosome of hematopoietic stem cells during
transplantation has not been studied sufficiently, and additional studies must be
performed to understand the long-term effects on those patients who received stem cell
transplants with iHHV-6.

Possible Pathologies Associated with Vertically Transmitted iHHV-6A/iHHV-6B
The documentation of integrated iHHV-6 also raises important questions. Is the
immune system of patients born with iHHV-6 tolerant of any viral antigens? Given that
the viral genome is present in every cell and capable of producing competent virions, are
these patients at particular risk for any diseases? Are the patients susceptible to
superinfection with another strain of HHV-6A, or to infection with HHV-6B? Answers to
these questions await further study.
HHV-6A and HHV-6B infection occurs by means of attachment and entry into
cells through the complement regulator receptor CD46 (25). The diverse cell tropism
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and multiple disease associations with HHV-6A/HHV-6B are due, in part, to the
expression of CD46 present on the surface of all nucleated cells. In particular, HHV-6B
primary infection of young children is the etiological agent of exanthema subitum
(roseola), which is characterized by high fever, diarrhea, and a mild skin rash along the
trunk, neck, and face (5, 12). There is no classic textbook clinical disease caused by
HHV-6A at this time. However, HHV-6A has been suggested to act as a co-factor in
AIDS progression by contributing to the killing of CD-4 lymphocytes (11, 20, 54) and
enhancement of HIV replication through activation of the long terminal repeats (LTR)
(21). Following primary infection, reactivation of HHV-6A/HHV-6B in immune
compromised patients has led to graft rejection in solid organ and bone marrow
transplants, seizures, and encephalitis (6, 16-19, 53).
Patients with iHHV-6 present a wide range of symptoms and various diseases
associated with the integrated viral genome, while other patients show no signs of
clinical disease (Table 12) (28-34, 64, 67, 98, 144). It remains unknown why some
patients’ manifest neurological symptoms of the disease and others don’t. However in
vitro iHHV-6 reactivation of patient T-cells (28, 33), suggests that the virus may be in a
latent integrated state in patients showing no signs of disease, while patients presenting
symptoms of disease may have iHHV-6 reactivated from its integrated state.
Furthermore, when considering the transmission of iHHV-6 through the germline, in every cell of the patient there is at least one integrated copy of the viral genome
(32, 33, 98, 143). Reactivation can occur in any number of tissues within the body of the
patient, which can lead to cell death, changes in cell function attributed to viral gene
expression, and subsequent spread to neighboring CD46+ cells. Therefore, the ability of
HHV-6A/HHV-6B to infect the majority of nucleated cells through CD46 and the
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presences of iHHV-6 integrated in every cell sheds light on the various symptoms and
diseases associated with this virus.
However pertaining to iHHV-6, the direct clinical link between neurological
disease and active viral replication is still underway. It remains uncertain if CNS
dysfunction is due to reactivation of iHHV-6 or if the virus is merely an opportunistic
infection within the brain. However, antiviral therapy has initially shown some short term
success in reducing neurological symptoms associated with iHHV-6 (148).

HHV-6A/HHV-6B and Malignant Diseases
Previous studies have evaluated patients with HHV-6A/HHV-6B presenting
neurological symptoms and various lymphomas, which include Hodgkin’s lymphoma,
Burkitt’s lymphoma, acute lympoblastic leukaemia (ALL), chronic myelogenous leukemia
(CML), and acute myeloid leukemia (AML) (28, 34, 110, 145, 149, 150). However, the
prevalence of HHV-6A/HHV-6B in children with ALL and AML does not differ significantly
from the healthy populations (150). Therefore the direct clinical link between cancer and
HHV-6A/HHV-6B is not completely conclusive, but reactivation of the virus can be linked
to graft rejection in hematopoietic stem cell transplant patients treated with
immunosuppressive drugs (16, 53).
HHV-6A/HHV-6B may not play a direct role in cancer development, but these
viruses may play a role in cancer progression by complementing oncogenic viruses in an
environment that condones cancer development. Similarly, HHV-6A has the ability to
increase HIV replication through activation of the long terminal repeats (LTR) and
enhance AIDS progression in macaques (20, 21). Also, HHV-6A/HHV-6B can increase
RNA expression of human papillomavirus virus (HPV) oncogenes E6 and E7 in cervical
epithelial cells (151). HHV-6A/HHV-6B and HPV co-infection of cervical epithelial cells
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increased production of E6 and E7 RNA and accelerated tumor growth in mice by 3
weeks as compared to the 6 week time period normally expected with HPV infection
alone.
During the course of human evolution, human endogenous retroviruses (HERV)
integrated into the germ-line roughly 10 million years ago (152). HERVs no longer
produce mature virus due to mutations and deletions in their sequence, however in a
study by zur Hausen et al., HHV-6 induced transcription of gag, pol, and env genes from
HERV found in normal PBMCs and in cell lines (153). Moreover, HERV env protein has
also been found to be expressed in various cancer cells. Duelli et al. hypothesized that
cell fusions caused by endogenous viruses and syncytium-forming viruses like HHV-6
can lead to aneuploidy and subsequently induce chromosome instability and malignant
transformation (154). Therefore the ability of HHV-6 and HERV to induce cell fusion,
and increase expression of HERV env protein by HHV-6, emphasizes the need of further
clinical studies to determine the potential impact of HHV-6 and iHHV-6 on cancer as well
as their effect on MS, CFS, DRESS, and bone marrow suppression in transplants.

Prevalence of Chromosome Integrated iHHV-6 in the Healthy Population; Not Yet
Identified Diseases?
To appreciate the significance of latent iHHV-6 integration into the telomere of
chromosomes, several studies have investigated the prevalence of iHHV-6 integration
amongst congenital infection, normal blood donors, and hospitalized patients (64, 65).
The prevalence of iHHV-6 chromosome integration with high viral loads (106-107 copies
per ml of blood) has been described in several British cohort studies (Table 13) (64, 65).
In normal healthy blood donors it was found that 0.8 % (4/500) (64) and 1.0 % (57/5638)
(81) had high viral loads most likely attributed to iHHV-6 integration in the germ-line. In
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contrast, prevalence of integrated iHHV-6 in hospitalized patient was higher, 2.9 %
(13/449) (64) and 3.3 % (6/184) (65). In conclusion, the transmission of iHHV-6 through
the germ-line and its prevalence in the population implies the necessity for research to
characterize the significance and possible pathologies of iHHV-6 integration. Moreover,
it is essential that researchers determine the overall impact the integrated virus may
have on hospitalized patients and understand disease progression associated with
iHHV-6.
Table 13. Prevalence of chromosome integrated iHHV-6 among patients and
blood donors.
Authors

Location

Individuals

Positive

Griffiths (155)

London, UK

Liver transplant pt

3/60 (5 %)

Kidd (156)

London, UK

Renal transplant pt

1/52 (1.9 %)

Ward (65)

London, UK

Encephalitis

6/184 (3.3 %)

Japan

Hospitalized pt

5/2332 (0.21 %)

Leong (64)

London, UK

Hospitalized pt

13/449 (2.9 %)

Ward (65)

London, UK

Blood donors

10/653 (1.5 %)

Leong (64)

London, UK

Blood donors

4/500 (0.8 %)

Hall (81)

Rochester,
NY

Cord blood donors

57/5638 (1.0 %)

Tanaka-Taya (32)

Summary and Future Directions
We hypothesized and established by a broad range of experiments that during
latency, the Human Herpesvirus 6A and 6B genome integrates into the telomeres of
human chromosomes through homologous recombination with the n(TTAGGG) viral
repeats, while transmission can occurs through the germ-line. Furthermore, we have
demonstrated the induction of the integrated virus to lytic replication. The second
objective of this dissertation was also achieved as the data contributes to our
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understanding of HHV-6A/HHV-6B latency and pathology as well as presents the current
and preceding knowledge of iHHV-6.
Since HHV-6A and HHV-6B are both important pathogens, our studies provide
several tools for future clinical investigations. Over 90% (or more likely 100%) of the
population has acquired a primary HHV-6 infection by three years of age and the virus
remains latent for the life of the host (13, 14). Investigators have established that HHV6B is the etiological agent of roseolla and HHV-6A is identified as a cofactor in AIDS
progression (6, 16-21, 53, 55-57). HHV-6A is perhaps associated with MS, while both
HHV-6A and HHV-6B are linked to graft rejection in transplants, and various neurological
disorders. Integration of HHV-6A and HHV-6B in telomeres may explain some of the
clinical symptoms associated with these diseases.
Future experiments need to determine the overall clinical impact of germ-line
integrated iHHV-6A/B. Furthermore, there is a need to determine the relationship
between HHV-6A/HHV-6B infection and MS, CFS, cancer, AIDS progression, and
various neurological disorders. Second, determine the physiological effect and impact
on the stability of iHHV-6 has on telomeres during integration. This questions is of
interest to investigators since telomere shortening leads to cell senescence and/or
telomerase activation, which is a hallmark of chromosome instability (69). Third,
characterize the molecular switches that dictate whether, following new infection in a cell
line capable of sustaining productive lytic infection, alternatively, the virus integrates and
establishes latency. Fourth, determine the switches that activate transcription of lytic
genes leading to reactivation of iHHV-6. Fifth, investigate whether the viral latency gene
ORF U94 and telomere binding proteins TRF1 and TRF2 do in fact play a role during the
process of telomere integration. Sixth, evaluate the effect of TPE on virus reactivation
and disruption of transcriptional repression of telomere adjacent chromosome genes.
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Seventh, determine if the TTAGGG repeats encoded in DR of HHV-7 promotes viral
telomere integration similar to HHV-6A/B and MDV.
The use of BAC vectors to clone the entire genome of herpesviruses are
instrumental in understanding the means by which viruses replicate, while the creation of
knockout-mutants characterize viral proteins. To begin to answer some of the questions
listed above, initial attempts to generate an infectious HHV-6 BAC cloned virus were
unsuccessful (46, 102). However, Arbuckle et al. were the first to successfully produce
an infectious HHV-6A virus that expresses GFP and a selectable marker (33). This
reproducible cloning system was then verified by Tang et al. (103). The knowledge
obtained from HHV-6A and HHV-6B integration and the adaptation of recombinant HHV6 viruses should facilitate understanding of the clinical impact viral latency/integration
has on the host.
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Fig. A1. Multiple sequence alignment of ORF U94 and direct repeat from
chromosomally integrated and reactivated iHHV-6A. ORF U94 was amplified with
primers U94L-1, U94L-2, U94R-1, and U94R-2; while the left repeat was amplified with
primers LTR-1 and LTR-2 from genomic DNA isolated from chromosomally integrated
family members. Alignments were completed with ClustalX 2.0 multiple sequence
alignment software.
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